Stock Purchase Agreement


 Exhibit 10.1 
 STOCK PURCHASE AGREEMENT 
 by and among 
 THE COLONIAL BANCGROUP, INC. 
 and

 THE PURCHASERS LISTED ON THE SIGNATURE PAGES HERETO 
 MARCH 31, 2009 






 TABLE OF CONTENTS 
  


					
	 ARTICLE 1
	  	Agreement to Sell and Purchase; Preferred Stock	  	1
			
	 1.1
	  	Agreement to Sell and Purchase	  	1
			
	 1.2
	  	Preferred Stock	  	1
			
	 ARTICLE 2
	  	Closing, Delivery and Payment	  	3
			
	 2.1
	  	Closing	  	3
			
	 2.2
	  	Delivery	  	3
			
	 2.3
	  	Anti-Dilution	  	3
			
	 ARTICLE 3
	  	Representations and Warranties of the Company	  	4
			
	 3.1
	  	Organization and Standing	  	4
			
	 3.2
	  	Company Capital Stock	  	5
			
	 3.3
	  	Corporate Power	  	6
			
	 3.4
	  	Corporate Authority	  	6
			
	 3.5
	  	Regulatory Approvals; No Violations	  	6
			
	 3.6
	  	Company Reports	  	7
			
	 3.7
	  	Financial Statements; Internal Controls	  	8
			
	 3.8
	  	Absence of Certain Changes	  	9
			
	 3.9
	  	Commitments and Contracts	  	10
			
	 3.10
	  	Title to and Sufficiency of Assets	  	12
			
	 3.11
	  	Compliance with Laws	  	13
			
	 3.12
	  	Litigation and Other Proceedings	  	13
			
	 3.13
	  	Taxes	  	14
			
	 3.14
	  	Compliance with ERISA	  	14
			
	 3.15
	  	Intellectual Property	  	15
			
	 3.16
	  	Related Party Transactions	  	15
			
	 3.17
	  	No Fees to Brokers or Other Persons	  	16
			
	 ARTICLE 4
	  	Representations and Warranties of Purchasers	  	16
			
	 4.1
	  	Institutional Accredited Investor; Experience	  	16
			
	 4.2
	  	Investment	  	16








					
			
	 4.3
	  	Organization and Standing	  	16
			
	 4.4
	  	Purchaser Power	  	16
			
	 4.5
	  	Purchaser Authority	  	16
			
	 4.6
	  	Regulatory Approvals; No Violations	  	17
			
	 4.7
	  	Expert Advice	  	17
			
	 4.8
	  	Financing	  	17
			
	 4.9
	  	Brokers and Finders	  	17
			
	 ARTICLE 5
	  	Covenants Relating to Conduct of Business	  	18
			
	 5.1
	  	Conduct of Business Prior to the Closing	  	18
			
	 5.2
	  	Company Forbearances	  	18
			
	 5.3
	  	Access; Information	  	20
			
	 ARTICLE 6
	  	Additional Agreements	  	21
			
	 6.1
	  	Commercially Reasonable Best Efforts	  	21
			
	 6.2
	  	Press Releases	  	21
			
	 6.3
	  	Regulatory Approvals	  	21
			
	 6.4
	  	NYSE Application; Amendment to Certificate of Incorporation	  	22
			
	 6.5
	  	No Solicitation	  	23
			
	 6.6
	  	Conversion Application	  	25
			
	 6.7
	  	Board Seats	  	25
			
	 6.8
	  	Preemptive Rights	  	26
			
	 6.9
	  	Restrictions on Transfer	  	28
			
	 6.10
	  	Indemnity for Purchasers	  	29
			
	 6.11
	  	Change in Control Agreements	  	29
			
	 ARTICLE 7
	  	Private Placement of the Shares; Registration Rights	  	30
			
	 7.1
	  	Securities Act Exemption	  	30
			
	 7.2
	  	Definitions	  	32
			
	 7.3
	  	Demand Registration	  	32
			
	 7.4
	  	Piggyback Registration	  	34
			
	 7.5
	  	Certain Registration Procedures	  	36
			
	 7.6
	  	Material Developments; Suspension of Offering	  	39
			
	 7.7
	  	Indemnification by the Company	  	40

  

 ii 








					
			
	 7.8
	  	Indemnification by Purchasers	  	41
			
	 7.9
	  	Conduct of Indemnification Proceedings	  	41
			
	 7.10
	  	Contribution	  	43
			
	 7.11
	  	Rule 144 Reporting	  	43
			
	 ARTICLE 8
	  	Conditions	  	44
			
	 8.1
	  	Conditions to Each Party’s Obligations to Close the Transaction	  	44
			
	 8.2
	  	Conditions to the Obligations of Purchasers	  	44
			
	 8.3
	  	Conditions to Closing of Company	  	46
			
	 ARTICLE 9
	  	Termination and Amendment	  	47
			
	 9.1
	  	Termination	  	47
			
	 9.2
	  	Effect of Termination	  	48
			
	 9.3
	  	Amendment	  	49
			
	 ARTICLE 10
	  	Miscellaneous	  	49
			
	 10.1
	  	Governing Law; Venue	  	49
			
	 10.2
	  	Attorney’s Fees	  	49
			
	 10.3
	  	Survival	  	49
			
	 10.4
	  	Successors and Assigns	  	50
			
	 10.5
	  	Entire Agreement	  	50
			
	 10.6
	  	Notices, Etc	  	50
			
	 10.7
	  	Specific Performance	  	51
			
	 10.8
	  	No Third Party Beneficiaries	  	51
			
	 10.9
	  	Several Obligations	  	51
			
	 10.10
	  	No Assignment	  	51
			
	 10.11
	  	Expenses	  	51
			
	 10.12
	  	Counterparts; Effectiveness	  	52
			
	 10.13
	  	Severability	  	52
			
	 10.14
	  	Titles and Subtitles	  	52
			
	 Exhibit A
	  	- Form of Certificate of Designations	  	
			
	 Schedule 1
	  	- Purchasers	  	

  

 iii 







 INDEX OF DEFINED TERMS 
  

							
	TERM	 	 	 	 	 	SECTION
	2010 Meeting	 		 		 	6.7(b)
	Acquisition Proposal	 		 		 	6.5(f)
	Affiliate	 		 		 	3.2(b)
	Agreement	 		 		 	Preamble
	ASBD	 		 		 	3.6(c)
	Authorizing Certificate	 		 		 	7.3(a)
	Board Representatives	 		 		 	6.7(a)
	Business Day	 		 		 	2.1
	Bylaws	 		 		 	3.1(c)
	Certificate of Designations	 		 		 	1.2
	Certificate of Incorporation	 		 		 	3.1(c)
	Claim	 		 		 	7.9(a)
	Closing	 		 		 	2.1
	Closing Date	 		 		 	2.1
	Code	 		 		 	3.14
	Company	 		 		 	Preamble
	Company Board	 		 		 	3.4
	Company Common Stock	 		 		 	1.2(a)
	Company Contract	 		 		 	3.9(a)
	Company Employee Benefit Plan	 		 		 	3.14
	Company Reports	 		 		 	3.6(a)
	Company Stock Option	 		 		 	3.2(b)
	Company Subsidiary	 		 		 	3.1(b)
	Covered Securities	 		 		 	6.8(a)
	Demand Notice	 		 		 	7.3(a)
	Demand Registration	 		 		 	7.3(a)
	Designated Securities	 		 		 	6.8(b)
	DGCL	 		 		 	1.2(a)
	Disclosure Schedule	 		 		 	Art. 3
	Effectiveness Date	 		 		 	7.3(b)(i)
	Effectiveness Period	 		 		 	7.3(b)(ii)
	Employees	 		 		 	5.2(i)
	ERISA	 		 		 	3.14
	Exchange Act	 		 		 	3.6(a)
	Executive Officers	 		 		 	3.8(b)
	FDIC	 		 		 	3.6(c)
	FRB	 		 		 	3.6(c)
	GAAP	 		 		 	3.1(b)
	Governmental Authority	 		 		 	3.5(a)
	Hedging Transaction	 		 		 	6.8(f)
	Indemnified Person	 		 		 	6.10
	Initiating Party	 		 		 	7.4(b)(ii)

  

 iv 








							
	Intellectual Property	 		 		 	3.15
	Legal Requirement	 		 		 	3.11
	Losses	 		 		 	6.10
	Material Adverse Effect	 		 		 	3.1(a)
	NYSE	 		 		 	3.5(a)
	OCC	 		 		 	3.6(c)
	Order	 		 		 	8.1(a)
	OTS	 		 		 	8.2(d)
	Person	 		 		 	7.2
	Piggyback Registration	 		 		 	7.4(a)
	Piggyback Shares	 		 		 	7.4(b)
	Preferred Stock	 		 		 	Recitals
	Price Per Share	 		 		 	1.1
	Private Placement	 		 		 	6.8(d)
	Purchase Price	 		 		 	1.1
	Purchaser Percentage Interest	 		 		 	6.8(a)
	Purchasers	 		 		 	Preamble
	Qualified Offering	 		 		 	6.8(a)
	Registrable Securities	 		 		 	7.2
	Registration Expenses	 		 		 	7.5(j)
	Registration Statement	 		 		 	7.2
	Registration Statement Filings	 		 		 	7.7(a)
	Regulation W Determination	 		 		 	6.3
	Regulatory Authority	 		 		 	3.6(c)
	Required Purchasers	 		 		 	5.1
	Resale Prospectus	 		 		 	7.7(c)
	Response Period	 		 		 	6.5(c)(ii)
	SEC	 		 		 	3.6(a)
	Securities Act	 		 		 	3.6(a)
	Series A Stock	 		 		 	Recitals
	Series B Stock	 		 		 	Recitals
	Shares	 		 		 	1.1
	Stockholder Approval	 		 		 	6.4(b)
	Superior Proposal	 		 		 	6.5(g)
	Tax	 		 		 	3.13
	Tax Return	 		 		 	3.13
	TBW	 		 		 	4.5
	Termination Date	 		 		 	9.1(a)
	Transaction	 		 		 	1.1
	Transfer	 		 		 	6.9
	Underwritten Offering	 		 		 	7.2

  

 v 







 STOCK PURCHASE AGREEMENT 
 This Stock Purchase Agreement (this “Agreement”) is made and entered into as of March 31, 2009, by and among The Colonial
BancGroup, Inc., a Delaware corporation (the “Company”), and each of the Purchasers listed on the signature pages hereto or Schedule 1 hereto (each a “Purchaser” and collectively,
“Purchasers”). 
 RECITALS 
 WHEREAS, the Company desires to issue and sell to Purchasers, and Purchasers desire to purchase from the Company, (a) certain shares of the Company’s Series A Voting Convertible Preferred Stock, par
value $2.50 per share (the “Series A Stock”), and (b) certain shares of the Company’s Series B Nonvoting Convertible Preferred Stock, par value $2.50 per share (the “Series B Stock” and, together with the
Series A Stock, the “Preferred Stock”), on the terms set forth herein. 
 NOW, THEREFORE, in consideration of the
foregoing recitals and the mutual promises, representations, warranties, covenants and agreements set forth herein, the parties hereto agree as follows: 
 ARTICLE 1 
 Agreement to Sell and Purchase; Preferred Stock 
 1.1 Agreement to Sell and Purchase. Subject to the terms and conditions hereof, Purchasers agree to purchase from the Company, on the
Closing Date, an aggregate of (a) 466,600 shares of Series A Stock and (b) 133,400 shares of Series B Stock ((a) and (b) collectively, the “Shares”), and the Company agrees to issue and sell such Shares to Purchasers,
at a price of Five Hundred and no/100 Dollars ($500.00) per Share (the “Price Per Share”) for an aggregate purchase price (the “Purchase Price”) equal to Three Hundred Million and no/100 Dollars ($300,000,000.00)
(such issuance, sale and purchase of the Shares, along with the other commitments by the parties set forth in this Agreement is referred to herein as the “Transaction”). 
 1.2 Preferred Stock. The designations, preferences and rights of the Series A Stock and the Series B Stock shall be substantially as set
forth in a Certificate of Designations (the “Certificate of Designations”), to be filed with the Delaware Secretary of State, substantially in the form attached hereto as Exhibit A. The Shares may be taken from the
Company’s authorized but unissued Preferred Stock, par value $2.50 per share as described in Article 4, Part D of the Certificate of Incorporation or the Company’s authorized but unissued Preference Stock, par value $2.50 per share, as
described in Article 4, Part A of the Certificate of Incorporation. A summary of the terms included in the Certificate of Designations is set forth below (provided, however, that in the event of any inconsistency between the general
description below and the terms set forth in the Certificate of Designations, the terms set forth in the Certificate of Designations shall control): 
 (a) Each share of Series A Stock shall be convertible, at the option of the holder thereof, into 1,000 shares of the Company’s common stock, par value $2.50 per share (the 







 
“Company Common Stock”), as adjusted for any stock split, combination, consolidation, stock distributions, stock dividends or the like, no
later than the later of (A) the date of the Company’s receipt of Stockholder Approval or the date that is three months after the Closing Date or (B) the date that is three months after the Closing Date provided that Stockholder
Approval has been received; provided, however, that in no event will such conversion take place if there are an insufficient number of authorized shares of Company Common Stock to effectuate such conversion. The holders of Series A
Stock shall have the right to vote, on an as-converted basis, with the Company Common Stock on all matters as and to the extent permitted by the Delaware General Corporation Law (the “DGCL”). In addition, so long as any share of
Series A Stock is outstanding, the affirmative vote of the holders of at least two-thirds of the shares of Series A Stock, voting separately as a class, whether or not a vote of the stockholders would otherwise be required by law, shall be required
for the Company to (i) amend, alter or repeal (by merger or otherwise) any provision of the Certificate of Incorporation or the Bylaws so as to affect adversely the relative rights, preferences, qualifications, limitations or restrictions of
the Series A Stock (other than to create or establish any capital stock to be issued to the United States Treasury as part of the TARP Capital Purchase Program or any similar governmental program), (ii) authorize or issue, or increase the
authorized amount of, any additional class or series of stock of the Company, or any security convertible into stock of such class or series, having rights senior to or pari passu with the Series A Stock as to dividends or liquidation (other
than any capital stock issued to the United States Treasury as part of the TARP Capital Purchase Program or any similar governmental program) and any right to vote, whether as a separate class or otherwise, on any matter (other than a matter that
can have no effect on the rights of the Series A Stock) as to which the Series A Stock is not entitled to vote, (iii) effect any reclassification of the Series A Stock, or (iv) enter into a merger or consolidation with, or sell or transfer
all or substantially all of its assets to, another person or entity. Holders of Series A Stock shall have preemptive rights with respect to future debt and equity securities issued by the Company, subject to certain exceptions. Holders of Series A
Stock also shall be entitled to receive cash dividends on an as-converted basis with the holders of Company Common Stock, whenever funds are legally available and when and as declared by the Company Board. Holders of Series A Stock shall not be
entitled to a liquidation preference, although they shall be entitled to receive liquidation proceeds on an as-converted basis with the holders of Company Common Stock. 
 (b) The rights and preferences of the Series B Stock shall be identical to that of the Series A Stock, except that holders of Series B Stock shall not have any voting powers, either general or special, except as may
be required by the DGCL; provided, however, that (A) if such shares of Series B Stock are held by TBW or any of its Affiliates, TBW’s or such Affiliate’s ability to convert such shares will be restricted as described in the
legend of the stock certificate(s) representing such shares and (B) so long as any share of Series B Stock is outstanding, the affirmative vote of the holders of at least two-thirds of the shares of Series B Stock, voting separately as a class,
whether or not a vote of the stockholders would otherwise be required by law, shall be required for the Company to (i) amend, alter or repeal (by merger or otherwise) any provision of the Certificate of Incorporation or the Bylaws so as to
affect adversely the relative rights, preferences, qualifications, limitations or restrictions of the Series B Stock (other than to create or establish any capital stock to be issued to the United States Treasury as part of the TARP Capital Purchase
Program or any similar governmental program), 

  

 2 







 
(ii) authorize or issue, or increase the authorized amount of, any additional class or series of stock of the Company, or any security convertible into stock
of such class or series, having rights senior to or pari passu with the Series B Stock as to dividends or liquidation (other than any capital stock issued to the United States Treasury as part of the TARP Capital Purchase Program or any
similar governmental program) and any right to vote, whether as a separate class or otherwise, on any matter (other than a matter that can have no effect on the rights of the Series B Stock) as to which the Series B Stock is not entitled to vote,
(iii) effect any reclassification of the Series B Stock, or (iv) enter into a merger or consolidation with, or sell or transfer all or substantially all of its assets to, another person or entity. 
 ARTICLE 2 
 Closing, Delivery and
Payment 
 2.1 Closing. Subject to the termination provisions set forth in Article 9, the closing (the
“Closing”) of the purchase and sale of the Shares shall take place at the offices of Locke Lord Bissell & Liddell LLP, 401 9th Street N.W., Suite 400 South, Washington, D.C. 20004, or at such other place as the parties
hereto may mutually agree, at 10:00 a.m., Washington, D.C. time, on (i) the fifth Business Day following the last to be waived or fulfilled of the conditions set forth in Article 8 (other than those conditions that by their nature are to be
satisfied at the Closing, but subject to the fulfillment or waiver of those conditions) or (ii) such other date and time as the parties hereto may mutually agree in writing. The date on which the Closing occurs is referred to herein as the
“Closing Date.” For purposes of this Agreement, a “Business Day” shall mean any day that is not a Saturday, Sunday or other day in which banks in Washington, D.C. are authorized or required by law to be closed.

 2.2 Delivery. At the Closing, subject to the terms and conditions hereof, the Company will deliver to Purchasers the Shares
in certificate form or via uncertificated book-entry form pursuant to instructions of Purchasers provided to the Company at least five (5) Business Days in advance of the Closing Date, free and clear of any liens or other encumbrances (other
than those placed thereon by or on behalf of Purchasers) and subject to any restrictions on resale in accordance with the terms of this Agreement and applicable law, and Purchasers will make payment to the Company of the Purchase Price, by wire
transfer of immediately available funds to an account designated by the Company in writing to Purchasers at least five (5) Business Days in advance of the Closing Date. Purchasers and the Company shall execute cross receipts acknowledging
receipt of the Shares and the Purchase Price, respectively. 
 2.3 Anti-Dilution. If, between the date of this Agreement and
the Closing Date, the outstanding shares of Company Common Stock shall have been changed into or exchanged for a different number, kind, class or series of shares or securities as a result of any reorganization, recapitalization, reclassification,
stock dividend, stock split, reverse stock split or other substantially similar transaction, an appropriate and proportionate adjustment shall be made to the number of Shares and the Price Per Share. 
  

 3 







 ARTICLE 3 
 Representations and Warranties of the Company 
 Except as disclosed (i) in the Company
Reports furnished or filed prior to the date of this Agreement (excluding any risk factor disclosures contained in such Company Reports under the heading “Risk Factors” and any disclosures of risks included in any “forward-looking
statements” disclaimer or other statements made that are similarly non-specific and are predictive or forward-looking in nature) or (ii) in the disclosure schedule delivered by the Company to Purchaser prior to the execution of this
Agreement (the “Disclosure Schedule”), which Disclosure Schedule sets forth items the disclosure of which is necessary or appropriate as an exception to one or more representations or warranties contained in this Article 3;
provided, however, that (A) the disclosure in any Section of the Disclosure Schedule shall apply only to the indicated Section of this Agreement except to the extent that it is apparent on the face of such disclosure that such disclosure
is relevant to another Section of this Agreement, and (B) notwithstanding anything in this Agreement to the contrary, the mere inclusion of an item as an exception to a representation or warranty shall not be deemed an admission that such item
represents a material exception or material fact, event or circumstance or that such item has had or would be reasonably likely to have a Material Adverse Effect, the Company hereby represents and warrants to Purchasers as follows: 
 3.1 Organization and Standing. 
 (a) The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company is duly qualified to transact business and is in good standing as a foreign corporation in each
jurisdiction where the ownership or operation of its assets or properties or conduct of its business requires such qualification, except where the failure to be so qualified or in good standing is not reasonably likely to have, individually or in
the aggregate, a Material Adverse Effect. As used in this Agreement, a “Material Adverse Effect” means any effect, circumstance, occurrence or change that is material and adverse to the business, assets, prospects, results of
operations or financial condition of the Company and Company Subsidiaries, taken as a whole; provided, however, that Material Adverse Effect shall not be deemed to include (i) any outbreak or escalation of hostilities, declared or
undeclared acts of war or terrorism, (ii) changes or proposed changes in GAAP or regulatory or accounting principles generally applicable to banks, savings associations and their holding companies (in the case of each of clause (i) and
(ii), other than effects, circumstances, occurrences or changes that arise after the date of this Agreement but before the Closing to the extent that such effects, circumstances, occurrences or changes have a materially disproportionate adverse
affect on the Company and Company Subsidiaries relative to other companies in the commercial banking industry), (iii) changes in the market price or trading volume of Company Common Stock (it being understood and agreed that the exception set
forth in this clause (iii) does not apply to the underlying reason or cause giving rise to or contributing to any such change), (iv) changes in the general economic or business conditions, including changes in interest or currency rates or
commodity prices, or (v) events, impacts or conditions caused by the negotiation, execution, announcement, or existence or terms of this Agreement or the performance of this Agreement or the consummation of the Transaction (including any
occurrence or condition arising out of the identity of or facts relating to Purchasers). 
  

 4 







 (b) Each Company Subsidiary is duly organized, validly existing and in good standing under the laws of
its jurisdiction of organization or incorporation. Each Company Subsidiary is duly qualified to transact business and is in good standing as a foreign corporation in each jurisdiction where the ownership or operation of its assets or properties or
conduct of its business requires such qualification, except where the failure to be so qualified or in good standing is not reasonably likely to have, individually or in the aggregate, a Material Adverse Effect. Other than the Company Subsidiaries
and securities held in its investment portfolio, neither the Company nor any Company Subsidiary owns any equity interest in any bank, corporation, partnership, limited liability company or other organization, whether incorporated or unincorporated.
As used in this Agreement, “Company Subsidiary” means any bank, corporation, partnership, limited liability company or other organization, whether incorporated or unincorporated, that is consolidated with the Company for financial
reporting purposes under U.S. generally accepted accounting principles (“GAAP”). 
 (c) The Company has delivered or made
available to Purchasers true, complete and correct copies of the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and Bylaws, as amended (the
“Bylaws”), and of the charter, bylaws and similar governing documents of each Company Subsidiary, each as in effect as of the date of this Agreement. 
 3.2 Company Capital Stock. 
 (a) As of the date hereof, the authorized capital stock of the
Company consists solely of 400,000,000 shares of Company Common Stock, of which 212,503,485 shares are issued and 202,536,758 shares are outstanding, 50,000,000 shares of Preferred Stock, none of which are issued and outstanding, and 1,000,000
shares of preference stock, par value $2.50 per share, none of which are issued and outstanding. The outstanding shares of Company Common Stock have been duly authorized and are validly issued, fully paid and nonassessable, and are not subject to
preemptive rights (and were not issued in violation of any preemptive rights). The Shares will be, as of the Closing, duly authorized by all necessary corporate action on the part of the Company and, when issued and delivered as provided in this
Agreement, will be duly and validly issued, fully paid and nonassessable, and the issuance thereof will not be subject to any preemptive rights. 
 (b) Except for Company Stock Options covering 4,149,530 shares of Company Common Stock as of the date hereof, there are no outstanding options, warrants or other rights in or with respect to the unissued shares of capital stock of the
Company nor any securities convertible into such stock, and the Company is not obligated to issue any additional shares of capital stock of the Company or any additional options, warrants or other rights in or with respect to the issued or unissued
shares of capital stock of the Company or any other securities convertible into such stock. As used in this Agreement, the term “Company Stock Option” means any option or right to acquire capital stock of the Company, or stock
appreciation right payable in cash issued pursuant to any Company Employee Benefit Plan or otherwise. There are no options, warrants, equity securities, calls, rights, commitments or agreements of any character obligating the Company or any Company
Subsidiary to grant, extend, accelerate the vesting of, otherwise modify or amend or enter into any such option, warrant, equity security, 

  

 5 







 
call, right, commitment or agreement. The Company does not have any outstanding stock appreciation rights, phantom stock, performance based rights or similar
rights or obligations. Neither the Company nor any of its Affiliates is a party to or is bound by any, and to the knowledge of the Company, there are no agreements with respect to the voting (including voting trusts and proxies) or sale or transfer
(including agreements imposing transfer restrictions) of any shares of capital stock or other equity interests of the Company. As used in this Agreement, “Affiliate” means, with respect to any person, any other person that directly
or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such person, and the term “control” (including the terms “controlled by” and “under common
control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such person, whether through ownership of voting securities, by contract or otherwise. 

3.3 Corporate Power. The Company and each Company Subsidiary has all requisite power and authority (corporate and other) to carry on its
business as it is now being conducted and to own, lease or operate all its properties and assets. The Company has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the
Transaction. 
 3.4 Corporate Authority. This Agreement and the Transaction have been duly authorized and approved by the board
of directors of the Company (the “Company Board”). The Company Board has determined that this Agreement and the Transaction are advisable and in the best interests of the Company and its stockholders. The Company’s Audit
Committee has unanimously and expressly approved, and the Company Board has unanimously concurred with, the Company’s reliance on the exemption under Paragraph 312.05 of the NYSE Listed Company Manual to issue the Shares without seeking a
stockholder vote. Prior to the Closing, the Company will have complied with all NYSE rules applicable to the Transaction. This Agreement and the Transaction have been authorized by all necessary corporate action of the Company, and no vote of the
holders of any class or series of the Company’s capital stock is necessary to approve and adopt this Agreement and to consummate the Transaction. This Agreement has been duly executed and delivered by the Company and, assuming the due
authorization, execution and delivery of this Agreement by Purchasers, this Agreement is a valid and legally binding agreement of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency,
reorganization, moratorium, fraudulent transfer and similar laws of general applicability relating to or affecting creditors’ rights or to general equity principles. 
 3.5 Regulatory Approvals; No Violations. 
 (a) No consents, approvals, permits, orders,
authorizations of, exemptions, reviews or waivers by, or notices, reports, filings, declarations or registrations with, any federal, state or local court, governmental, legislative, judicial, administrative or regulatory authority, agency,
commission, body or other governmental entity or self regulatory organization (each, a “Governmental Authority”) or with any other third party are required to be made or obtained by the Company or any Company Subsidiary in
connection with the execution, delivery and performance by the Company of this Agreement or the consummation of the purchase of the 

  

 6 







 
Shares or any other aspect of the Transaction except for (i) those already obtained or made, (ii) the filings contemplated by Section 6.3,
(iii) required filings with the New York Stock Exchange (the “NYSE”) or the SEC in connection with the matters contemplated under Section 6.4 or otherwise, (iv) the filings contemplated by Article 7, and (v) any
securities or “blue sky” filings of any state. The Company knows of no reason why all regulatory approvals from any Governmental Authority required for the consummation of the Transaction should not be obtained on a timely basis.

 (b) The execution, delivery and performance of this Agreement by the Company does not, and the consummation by the Company of the
Transaction will not, (i) constitute or result in a breach or violation of, or a default under, the acceleration of any obligations or penalties or the creation of any charge, mortgage, pledge, security interest, restriction, claim, lien,
equity, encumbrance or any other encumbrance or exception to title of any kind on any assets or any indebtedness of the Company or any Company Subsidiaries (with or without notice, lapse of time, or both) pursuant to, agreements binding upon the
Company or any Company Subsidiary or to which the Company or any Company Subsidiary or any of their respective properties is subject or bound or any law, regulation, judgment or governmental or non-governmental permit or license to which the Company
or any Company Subsidiary or any of their respective properties is subject, (ii) constitute or result in a breach or violation of, or a default under, the Certificate of Incorporation or the Bylaws or the charter, bylaws or similar governing
documents of any Company Subsidiary or (iii) require any consent or approval or notice or other filing under any such agreement, law, regulation, judgment, governmental or non-governmental permit or license, except, in the case of clauses
(i) or (iii) above, for any breach, violation, default, acceleration, creation, change, consent or approval that, individually or in the aggregate, is not reasonably likely to have a Material Adverse Effect. 
 3.6 Company Reports. 
 (a) The
Company and each Company Subsidiary has filed or furnished, as applicable, on a timely basis all forms, filings, registrations, submissions, statements, certifications, reports and documents required to be filed or furnished by it with the U.S.
Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”) or the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since
December 31, 2005 (the forms, statements, reports and documents filed or furnished since December 31, 2005 and through the date hereof, including any amendments thereto, the “Company Reports”). Each of the Company Reports,
at the time of its filing or being furnished complied, or if not yet filed or furnished, will comply, in all material respects with the applicable requirements of the Securities Act and the Exchange Act, and any rules and regulations promulgated
thereunder applicable to the Company Reports. As of their respective dates (or, if amended prior to the date hereof, as of the date of such amendment), the Company Reports did not, and any Company Reports filed or furnished with the SEC subsequent
to the date hereof will not, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances in which they were made, not
misleading. 
  

 7 







 (b) The Company is in compliance in all material respects with the applicable listing and corporate
governance rules and regulations of the NYSE. 
 (c) The Company and Company Subsidiaries have timely filed all reports and statements,
together with any amendments required to be made with respect thereto, that they were required to file since December 31, 2005 with the Board of Governors of the Federal Reserve System (the “FRB”), the Federal Deposit Insurance
Corporation (the “FDIC”), the Office of the Comptroller of the Currency (the “OCC”), the Alabama State Banking Department (the “ASBD”), or any other Governmental Authority having jurisdiction over
its business or any of its assets or properties (each a “Regulatory Authority”), and all other material reports and statements required to be filed by it since December 31, 2005, including, without limitation, the rules and
regulations of the FDIC, the OCC, the ASBD or any other Regulatory Authority, and has paid all fees and assessments due and payable in connection therewith. As of their respective dates, such reports and statements complied in all material respects
with all the laws, rules and regulations of the applicable Regulatory Authority with which they were filed. 
 3.7 Financial
Statements; Internal Controls. 
 (a) The Company’s consolidated financial statements (including, in each case, any notes
thereto) contained in the Company Reports, were or will be prepared (i) in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto or, in the case of interim
consolidated financial statements, where information and footnotes contained in such financial statements are not required under the rules of the SEC to be in compliance with GAAP) and (ii) to comply as to form, as of their respective date of
filing with the SEC, in all material respects with applicable accounting requirements and with the published rules and regulations of the SEC with respect thereto, and in each case such consolidated financial statements fairly presented, in all
material respects, the consolidated financial position, results of operations, changes in stockholder equity and cash flows of the Company and the consolidated Company Subsidiaries as of the respective dates thereof and for the respective periods
covered thereby (subject, in the case of unaudited statements, to normal year-end adjustments which were not and which are not expected to be, individually or in the aggregate, material to the Company and its consolidated Company Subsidiaries taken
as a whole). 
 (b) Neither the Company nor any of the Company Subsidiaries has any material liability or obligation of any nature whatsoever
(whether absolute, accrued, contingent, determined, determinable or otherwise and whether due or to become due), except for (i) those liabilities that are reflected or reserved against on the consolidated balance sheet of the Company included
in its Annual Report on Form 10-K for the fiscal year ended December 31, 2008 (including any notes thereto) and (ii) liabilities incurred in the ordinary course of business consistent with past practice since December 31, 2008 or in
connection with this Agreement and the Transaction. 
 (c) The Company maintains disclosure controls and procedures required by Rule 13a-15
or 15d-15 under the Exchange Act. Such disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company is recorded and 

  

 8 







 
reported on a timely basis to the individuals responsible for the preparation of the Company’s filings with the SEC and other public disclosure
documents. The Company maintains internal control over financial reporting (as defined in Rule 13a-15 or 15d-15, as applicable, under the Exchange Act). Such internal control over financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes policies and procedures that (i) pertain to the maintenance of records that in reasonable
detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company, and (iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on its financial statements. 
 (d) The Company has disclosed, based on the most recent evaluation of its chief executive officer and its chief financial officer prior to the date hereof, to the Company’s auditors and the audit committee of the Company Board
(i) any significant deficiencies and material weaknesses in the design or operation of its internal control over financial reporting that are reasonably likely to adversely affect the Company’s ability to record, process, summarize and
report financial information and has identified for the Company’s auditors and audit committee of the Company Board any material weaknesses in internal control over financial reporting and (ii) any fraud, whether or not material, that
involves management or other employees who have a significant role in the Company’s internal control over financial reporting. Since December 31, 2005, no material complaints, allegation, assertion or claim, whether written or oral from
any source regarding accounting, internal accounting controls or auditing matters, and no concerns from the Company employees regarding questionable accounting or auditing matters, have been received by the Company. No attorney representing the
Company or any Company Subsidiary, whether or not employed by the Company or any Company Subsidiary, has reported evidence of a violation of securities laws, breach of fiduciary duty or similar violation by the Company or any of its officers,
directors, employees or agents to the Company’s chief legal officer, audit committee (or other committee designated for the purpose) of the Company Board or the Company Board pursuant to the rules adopted under Section 307 of the
Sarbanes-Oxley Act. 
 3.8 Absence of Certain Changes. 
 (a) Since December 31, 2008, (i) the Company and Company Subsidiaries have conducted their respective businesses in all material respects in the
ordinary course, consistent with prior practice, and (ii) no event or events have occurred that have had or would be reasonably likely to have, individually or in the aggregate, a Material Adverse Effect. 
 (b) Since December 31, 2008, neither the Company nor any of the Company Subsidiaries has (i) except for (A) normal increases for or
payments to employees (other than officers subject to the reporting requirements of Section 16(a) of the Exchange Act (the “Executive Officers”)) made in the ordinary course of business consistent with past practice or 

  

 9 







 
(B) as required by applicable law or contractual obligations existing as of the date hereof that are disclosed in the Company Reports or the Disclosure
Schedule, increased the wages, salaries, compensation, pension, or other fringe benefits or perquisites payable to any Executive Officer or other employee or director from the amount thereof in effect as of December 31, 2008, granted any
severance or termination pay, entered into any contract to make or grant any severance or termination pay, or paid any cash bonus in excess of $1 million, (ii) granted any options to purchase shares of Company Common Stock, any restricted
shares of Company Common Stock or any right to acquire any shares of its capital stock, or any right to payment based on the value of the Company’s capital stock, to any Executive Officer or other employee or director other than grants to
employees (other than Executive Officers) made in the ordinary course of business consistent with past practice or grants relating to shares of Company Common Stock with an aggregate value for all such grants of less than $1 million for any
individual, (iii) changed any financial accounting methods, principles or practices of Company or the Company Subsidiaries affecting its assets, liabilities or businesses, including any reserving, renewal or residual method, practice or policy,
(iv) suffered any strike, work stoppage, slow-down, or other labor disturbance, or (v) except for publicly disclosed ordinary dividends on the Company Common Stock and except for distributions by wholly-owned Company Subsidiaries to
Company or another wholly-owned Company Subsidiary, made or declared any distribution in cash or kind to its stockholder or repurchased any shares of its capital stock or other equity interests. 
 3.9 Commitments and Contracts. 
 (a) Neither the Company nor any of the Company Subsidiaries is a party to or otherwise subject to or bound by: 
 (i) any
employment, deferred compensation, bonus or consulting contract that (A) has a remaining term, as of the date of this Agreement, of more than one year in length of obligation on the part of the Company or any of the Company Subsidiaries and is
not terminable by the Company or any of the Company Subsidiaries within one year without penalty or (B) requires payment by the Company or any of the Company Subsidiaries of $100,000 or more per annum; 
 (ii) any advertising, brokerage, distributor, representative or agency relationship or contract requiring payment by the Company or any of the Company
Subsidiaries of $500,000 or more per annum; 
 (iii) any contract or agreement that restricts the Company or any of the Company Subsidiaries
(or would restrict the Company, any Affiliate of the Company or any of the Company Subsidiaries upon consummation of the Transaction) from competing in any line of business with any bank, corporation, partnership, limited liability company or other
organization, whether incorporated or unincorporated, or other person; 
 (iv) any contract or agreement that obligates the Company or any
of the Company Subsidiaries to conduct business on an exclusive or preferential basis with any third party or, upon consummation of the Transaction, will obligate the Company or any of the Company Subsidiaries to conduct business with any third
party on an exclusive or preferential basis, in any case of the preceding which is material; 
  

 10 







 (v) any lease of real or personal tangible property providing for annual lease payments by or to the
Company or any of the Company Subsidiaries in excess of $500,000 per annum; 
 (vi) any material license agreement granting any right to use
or practice any right under any material Intellectual Property (whether as licensor or licensee), excluding ordinary course of business customer contracts; 
 (vii) any agreement in which the Company or any of the Company Subsidiaries covenanted not to assert any right in any Intellectual Property to a third party, excluding customer contracts in ordinary course of business
and confidentiality agreements; 
 (viii) any stock purchase, stock option, stock bonus, stock ownership, profit sharing, group insurance,
bonus, deferred compensation, severance pay, pension, retirement, savings or other incentive, welfare or employment plan or material agreement providing benefits to any present or former employees, officers or directors of the Company or any Company
Subsidiary; 
 (ix) any contract or agreement with or to a labor union or guild (including any collective bargaining agreement); 

(x) any agreement to acquire equipment or any commitment to make capital expenditures of $500,000 or more; 
 (xi) other than agreements entered into in the ordinary course of business, any agreement for the sale of any material property or assets in which the
Company or any Company Subsidiary has an ownership interest or for the grant of any lien, pledge or other encumbrance on any such property or asset; 
 (xii) any agreement for the borrowing of any money and any guaranty agreement; 
 (xiii) any partnership or
joint venture agreement; 
 (xiv) any material agreement which would be terminable other than by the Company or any Company Subsidiary as a
result of the consummation of the transactions contemplated by this Agreement; 
 (xv) other than agreements entered into in the ordinary
course of business, any other agreement of any other kind which involves future payments or receipts or performances of services or delivery of items requiring payment of $500,000 or more to or by the Company or any Company Subsidiary; or

  

 11 







 (xvi) any other contract or agreement that is a “material contract” (as such term is defined
in Item 601(b)(10) of Regulation S-K of the SEC) to be performed after the date of this Agreement that has not been filed or incorporated by reference in the Company Reports filed prior to the date hereof. 
 Each contract, arrangement, commitment or understanding of the type described in this Section 3.9(a) is referred to as a “Company Contract.”

 (b) The Company has publicly disclosed in the Company Reports filed with the SEC, or has provided to Purchasers prior to the date hereof
or will promptly provide for review during the due diligence period (by hard copy, electronic data room or otherwise), true, correct and complete copies of, each Company Contract. Each Company Contract is in full force and effect and enforceable in
accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and similar laws of general applicability relating to or affecting creditors’ rights or to general equity principles. No event or
condition exists that constitutes or, after notice or lapse of time or both, will constitute, a breach, violation or default on the part of the Company or any of the Company Subsidiaries or, to the Company’s knowledge, any other party thereto
under any such Company Contract. There are no disputes pending or, to Company’s knowledge, threatened with respect to any Company Contract. 
 3.10 Title to and Sufficiency of Assets. 
 (a) The Company and each Company Subsidiary has good and marketable title
to all assets and properties, whether real or personal, tangible or intangible, that it purports to own, subject to no valid liens, mortgages, security interests, encumbrances or charges of any kind except: (i) as noted in the Company Reports;
(ii) statutory liens for taxes not yet delinquent or being contested in good faith by appropriate proceedings and for which appropriate reserves have been established and reflected on the Company’s financial statements; (iii) pledges
or liens required to be granted in connection with the acceptance of government deposits, granted in connection with repurchase or reverse repurchase agreements, pursuant to borrowings incurred in the ordinary course of business; and
(iv) defects and irregularities in title and encumbrances that do not materially impair the use thereof for the purposes for which they are held. The Company and each Company Subsidiary as lessee has the right under valid and existing leases to
occupy, use, possess and control any and all of the respective properties leased by it. Except where any failure would not have a Material Adverse Effect, all buildings and structures owned by the Company and each Company Subsidiary lie wholly
within the boundaries of the real property owned or validly leased by it, and do not encroach upon the property of, or otherwise conflict with the property rights of, any other person or entity. 
 (b) The buildings, structures and equipment of the Company and the Company Subsidiaries are structurally sound, are in good operating condition and
repair, and are adequate for the uses to which they are being put, and none of such buildings, structures or equipment is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in the aggregate
in nature or in cost. Except where any failure would not have a Material Adverse Effect, the real property, buildings, structures and equipment owned or leased by the Company and the Company Subsidiaries are in compliance with all Legal 

  

 12 







 
Requirements, including building and development codes and other restrictions, subdivision regulations, building and construction regulations, drainage
codes, environmental, health, fire and safety laws and regulations, utility tariffs and regulations, conservation laws and zoning laws and ordinances. The assets and properties, whether real or personal, tangible or intangible, that the Company or
any Company Subsidiary purports to own are sufficient for the continued conduct of the business of each of the Company and such Company Subsidiary after the Closing in substantially the same manner as conducted prior to the Closing. 
 3.11 Compliance with Laws. The Company and each Company Subsidiary holds all material licenses, certificates, permits, franchises and
rights from all appropriate Regulatory Authorities necessary for the conduct of its respective business. The Company and each Company Subsidiary is, and at all times since January 1, 2006 has been, in compliance with each law that is or was
applicable to it or to the conduct or operation of its respective businesses or the ownership or use of any of its respective assets (a “Legal Requirement”), except where the failure to comply would not have a Material Adverse
Effect. No event has occurred or circumstance exists that (with or without notice or lapse of time): (i) may constitute or result in a violation by the Company or a Company Subsidiary of, or a failure on the part of the Company or a Company
Subsidiary to comply with, any Legal Requirement; or (ii) may give rise to any obligation on the part of the Company or a Company Subsidiary to undertake, or to bear all or any portion of the cost of, any remedial action of any nature in
connection with a failure to comply with any Legal Requirement; except, in either case, where the failure to comply or the violation would not have a Material Adverse Effect. Neither the Company nor any Company Subsidiary has received, at any time
since January 1, 2006, any notice or other communication (whether oral or written) from any Regulatory Authority or any other person or entity, nor does the Company have any knowledge regarding: (A) any actual, alleged, possible or
potential violation of, or failure to comply with, any Legal Requirement; or (B) any actual, alleged, possible or potential obligation on the part of the Company or a Company Subsidiary to undertake, or to bear all or any portion of the cost
of, any remedial action of any nature in connection with a failure to comply with any Legal Requirement, except where any such violation, failure or obligation would not have a Material Adverse Effect. 
 3.12 Litigation and Other Proceedings. 
 (a) (i) No civil, criminal or administrative litigation, claim, action, suit, hearing, arbitration, investigation or other proceeding before any Governmental Authority or arbitrator is pending or, to the knowledge of the Company, threatened
against the Company or any Company Subsidiary, (ii) neither the Company or any Company Subsidiary is subject to any order, judgment or decree, and (iii) there are no facts or circumstances that could result in any claims against, or
obligations or liabilities of, the Company or any Company Subsidiary, except with respect to (i), (ii) and (iii) for those that are not, individually or in the aggregate, reasonably likely to have a Material Adverse Effect. 
 (b) Neither the Company nor any Company Subsidiary: (i) is subject to any cease and desist or other order or enforcement action issued by, or
(ii) is a party to any written agreement, consent agreement or memorandum of understanding with, or (iii) is a party to any commitment letter or similar undertaking to, or (iv) is subject to any order or directive by, or 

  

 13 







 
(v) is subject to any supervisory letter from, or (vi) has been ordered to pay any civil money penalty, which has not been paid, by, or
(vii) has adopted any policies, procedures or board resolutions at the request of, any Regulatory Authority that currently (A) restricts in any material respect the conduct of its business, or (B) in any material manner relates to its
capital adequacy, or (C) restricts its ability to pay dividends, or (D) limits in any material manner its credit or risk management policies, its management or its business; nor has the Company or any Company Subsidiary been advised by any
Regulatory Authority that it is considering issuing, initiating, ordering or requesting any of the foregoing or that it has initiated any investigation or proceeding into the business or operations of the Company or a Company Subsidiary. 

3.13 Taxes. The Company and each Company Subsidiary have each duly filed all material Tax Returns required to be filed by it, and each
such Tax Return is complete and accurate in all material respects. The Company and each Company Subsidiary have each paid, or made adequate provision for the payment of, all Taxes (whether or not reflected in Tax Returns as filed or to be filed) due
and payable by the Company or the Company Subsidiary, or claimed to be due and payable by any Regulatory Authority, and is not delinquent in the payment of any Tax, except such Taxes as are being contested in good faith and as for which adequate
reserves have been provided or otherwise involving non-material amounts. There is no claim or assessment pending or, to the knowledge of the Company, threatened against the Company or any Company Subsidiary for any Taxes owed by any of them. No
audit, examination or investigation related to Taxes paid or payable by the Company or any Company Subsidiary is presently being conducted or, to the knowledge of the Company, threatened by any Regulatory Authority. The Company has delivered or made
available to Purchasers true, correct and complete copies of all Tax Returns filed with respect to the last three fiscal years by the Company and the Company Subsidiaries and any tax examination reports and statements of deficiencies assessed or
agreed to for the Company or any Company Subsidiary for any such time period. For purposes of this Section 3.13: “Tax” means any tax (including any income tax, capital gains tax, value added tax, sales tax, property tax, gift
tax or estate tax), levy, assessment, tariff, duty (including any customs duty), deficiency or other fee, and any related charge or amount (including any fine, penalty, interest or addition to tax), imposed, assessed or collected by or under the
authority of any Governmental Authority or payable pursuant to any Legal Requirement, tax sharing agreement or any other contract relating to the sharing or payment of any such tax, levy, assessment, tariff, duty, deficiency or fee; and “Tax
Return” means any return (including any information return), report, statement, schedule, notice, form or other document or information filed with or submitted to, or required to be filed with or submitted to, any Governmental Authority in
connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation, or enforcement of or compliance with any Legal Requirement relating to any Tax. 
 3.14 Compliance with ERISA. All employee benefit plans (as defined in Section 3(3) of the Employee Retirement Income Security
Act of 1974, as amended (“ERISA”)) and all Company Employee Benefit Plans established or maintained by the Company or a Company Subsidiary or to which the Company or a Company Subsidiary contributes, are in material compliance with
all applicable requirements of ERISA, and are in material compliance with all applicable requirements (including qualification and non-discrimination requirements in effect as of the Closing) of the Internal Revenue Code of 1986, as amended (the
“Code”) for obtaining the 

  

 14 







 
tax benefits the Code thereupon permits with respect to such employee benefit plans. No such employee benefit plan has any amount of unfunded benefit
liabilities (as defined in Section 4001(a)(18) of ERISA) for which the Company or any Company Subsidiary would be liable to any person under Title IV of ERISA if any such employee benefit plan were terminated as of the Closing. Such
employee benefit plans are funded in accordance with Section 412 of the Code (if applicable). There would be no material obligations of the Company or any Company Subsidiary under Title IV of ERISA relating to any such employee
benefit plan that is a multi-employer plan if any such plan were terminated or if the Company or a Company Subsidiary withdrew from any such plan as of the Closing. All contributions and premium payments that are due under any such benefit plans
have been made. No Company Employee Benefit Plan has engaged in or been a party to a “prohibited transaction” (as defined in Section 406 of ERISA or Section 4975(c) of the Code) without an exemption thereto under Section 408
of ERISA or Section 4975(d) of the Code. The Transaction will not constitute a change in control under any Company Employee Benefit Plan. For purposes of this Agreement, the term “Company Employee Benefit Plan” means each
profit sharing, group insurance, hospitalization, stock option, pension, retirement, bonus, severance, change of control, deferred compensation, stock bonus, stock purchase, employee stock ownership or other employee welfare or benefit agreement,
plan or arrangement established, maintained, sponsored or undertaken by the Company or any Company Subsidiary for the benefit of the officers, directors or employees of the Company or the Company Subsidiary, including each trust or other agreement
with any custodian or any trustee for funds held under any such agreement, plan or arrangement, and all other contracts or arrangements under which pensions, deferred compensation or other retirement benefits are being paid or may become payable by
the Company or the Company Subsidiary for the benefit of the directors, officers or employees of the Company or the Company Subsidiary. 
 3.15 Intellectual Property. The Company has provided to purchaser, prior to the date hereof, a true, correct and complete listing and description of all the material patents, copyrights, trademarks, trade names, service marks,
trade dress and logos (and all registrations and applications with respect thereto) (collectively, with the goodwill of the business symbolized thereby, the “Intellectual Property”) used in the business of the Company or any Company
Subsidiary. The Company and each Company Subsidiary owns or possesses a valid and binding license or otherwise is duly authorized to use all of the Intellectual Property used by it. Neither the Company nor any Company Subsidiary is in material
default under any license, contract, agreement, arrangement or commitment related to any of the Intellectual Property. Such Intellectual Property as used by the Company or a Company Subsidiary in its business do not violate or infringe upon the
proprietary rights of any third party in any material respect, and there is no claim, action, proceeding or investigation pending or, to the Company’s knowledge, threatened against the Company or any Company Subsidiary with respect to any such
Intellectual Property. 
 3.16 Related Party Transactions. Neither the Company nor any Company Subsidiary has made any loan to
any director, officer or other Affiliate of the Company or any Company Subsidiary which remains outstanding nor has the Company or any Company Subsidiary entered into any agreement for the purchase or sale of any property (other than equity
securities of the Company) or services from or to any director, officer or other Affiliate of the Company or any Company Subsidiary. All loans to executive officers and directors (and related interests) have been made in compliance with FRB
Regulation O (12 C.F.R. Part 215). 
  

 15 







 3.17 No Fees to Brokers or Other Persons. Neither the Company nor any Company Subsidiary
nor any of their respective officers, directors, employees, agents or representatives (i) has employed any broker, investment banker or finder or incurred any liability for any brokerage or investment banking fees, commissions or finders or
similar fees in connection with the Transaction or (ii) has incurred any liability for any termination, break-up or similar fees in connection with the Transaction or any Acquisition Proposal. 
 ARTICLE 4 
 Representations and
Warranties of Purchasers 
 Each Purchaser, severally and not jointly, hereby represents and warrants to the Company as follows:

 4.1 Institutional Accredited Investor; Experience. Purchaser is an “accredited investor” (as defined in Rule 501
under the Securities Act) and is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. 
 4.2 Investment. Purchaser is acquiring the Shares for investment for its own account for investment purposes, and not with the view to, or for resale in connection with, any distribution thereof that
would require the issuance of the Shares pursuant to this Agreement to be registered under the Securities Act. 
 4.3 Organization and
Standing. Purchaser is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization or incorporation. Purchaser is duly qualified to do business and is in good standing as a foreign entity in each
jurisdiction where the ownership or operation of its assets or properties or conduct of its business requires such qualification, except where the failure to be so qualified or in good standing is not reasonably likely to have, individually or in
the aggregate, a material adverse effect on the ability of Purchaser to timely consummate the Transaction. 
 4.4 Purchaser Power.
Purchaser has all requisite company power and authority and has taken all company action necessary in order to execute, deliver and perform its obligations under this Agreement and to consummate the Transaction. 
 4.5 Purchaser Authority. This Agreement and the Transaction have been duly authorized by all necessary company action of Purchaser. Subject
to the last sentence of this Section 4.5, this Agreement has been duly executed and delivered by Purchaser, and, assuming the due authorization, execution and delivery of this Agreement by the Company, this Agreement is a valid and legally
binding agreement of Purchaser, enforceable against Purchaser in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and similar laws of general applicability relating to or affecting
creditors’ rights or to general equity principles. The Purchasers listed on Schedule 1 have not executed this Agreement as of March 31, 2009. Taylor, Bean & Whitaker Mortgage Corp. (“TBW”) is signing this
Agreement on behalf of the Purchasers listed on Schedule 1 hereto. 
  

 16 







 4.6 Regulatory Approvals; No Violations. 
 (a) No consents, approvals, permits, orders or authorizations of, exemptions, reviews or waivers by, or notices, reports, filings or registrations with
any Governmental Authority or with any other third party are required to be made or obtained by Purchaser or any of its Affiliates or any of their respective officers, directors or employees in connection with the execution, delivery and performance
by Purchaser of this Agreement or the consummation of the Transaction except for (i) those already obtained or made and (ii) the filings contemplated by Section 6.3. Purchaser knows of no reason why all regulatory approvals from any
Governmental Authority required for the consummation of the Transaction should not be obtained on a timely basis. 
 (b) The execution,
delivery, and performance of this Agreement by Purchaser does not, and the consummation by Purchaser of the Transaction will not, (i) constitute or result in a breach or violation of, or a default under, or the acceleration or creation of any
obligations, penalties or the creation of any charge, mortgage, pledge, security interest, restriction, claim, lien or equity, encumbrance or any other encumbrance or exception to title of any kind on the assets or properties of Purchaser (with or
without notice, lapse of time, or both) pursuant to agreements binding upon Purchaser or to which Purchaser or any of its properties is subject or bound or any law, regulation, judgment or governmental or non-governmental permit or license to which
Purchaser or any of its properties is subject, (ii) constitute or result in a breach or violation of, or a default under, the organizational documents of Purchaser or (iii) require any consent or approval under any such agreement, law,
regulation, judgment, governmental or non-governmental permit or license (other than those contemplated by Section 4.6(a)), except, in the case of clauses (i) or (iii) above, for any breach, violation, default, acceleration, creation,
change, consent or approval that, individually or in the aggregate, is not reasonably likely to have a material adverse effect on the ability of Purchaser to timely consummate the Transaction. 
 4.7 Expert Advice. Purchaser has independently evaluated the Transaction and has consulted its own experts necessary to determine that the
investment pursuant to the Transaction is appropriate for such Purchaser. 
 4.8 Financing. Purchaser has used and will
continue to use commercially reasonable best efforts to obtain the funds necessary to complete the Transaction or to obtain approval for financing the Transaction subject to ordinary closing contingencies. Each Purchaser (or shareholder, member or
partner of Purchaser, as the case may be) has deposited into an escrow account an amount equal to ten percent (10%) of such Purchaser’s (or shareholder’s, member’s or partner’s, as the case may be) respective portion of the
Purchase Price. On or prior to the date of this Agreement, Purchaser has delivered to the Company evidence of the financing commitment and escrowed amount relating to such Purchaser. 
 4.9 Brokers and Finders. Except as set forth in Section 3.17, neither Purchaser nor its affiliates, any of their respective officers,
directors, employees or agents has employed any 

  

 17 







 
broker or finder or incurred any liability for any financial advisory fees, brokerage fees, commissions, or finder’s fees, and no broker or finder has
acted directly or indirectly for Purchaser, in connection with this Agreement or the Transaction, in each case, whose fees the Company would be required to pay. 
 ARTICLE 5 
 Covenants Relating to Conduct of Business 
 5.1 Conduct of Business Prior to the Closing. Except as otherwise expressly contemplated or permitted by this Agreement or with the prior
written consent of Purchasers holding the right to acquire (or, if after the Closing, holding) at least a majority of the aggregate Shares to be purchased (or, if after the Closing, purchased) hereunder (the “Required Purchasers”)
(which consent shall not be unreasonably withheld or delayed), during the period from the date of this Agreement to the Closing Date, the Company shall, and shall cause each Company Subsidiary to, (i) conduct its business only in the usual,
regular and ordinary course consistent with past practice and (ii) take no action which would reasonably be expected to adversely affect or delay (A) the receipt of any approvals of any Governmental Authority required to consummate the
transactions contemplated hereby or (B) the consummation of the transactions contemplated hereby. 
 5.2 Company
Forbearances. Except as expressly contemplated or permitted by this Agreement, during the period from the date of this Agreement to the Closing, the Company shall not, and shall not permit any Company Subsidiary to, without the prior written
consent of the Required Purchasers (which consent shall not be unreasonably withheld or delayed): 
 (a) (i) Issue, sell or otherwise permit
to become outstanding, or dispose of or encumber or pledge, or authorize or propose the creation of, any additional shares of its stock (other than pursuant to the exercise of Company Stock Options outstanding as of the date hereof or other than any
capital stock issued to the United States Treasury as part of the TARP Capital Purchase Program or any similar governmental program), or (ii) permit any additional shares of its stock to become subject to new grants, except issuances under
dividend reinvestment plans in the ordinary course of business; 
 (b) Make, declare, pay or set aside for payment any dividend on or in
respect of, or declare or make any distribution on any shares of its stock, other than (i) regular quarterly dividends on its common stock at a rate no greater than the rate paid by it during the fiscal quarter immediately preceding the date
hereof, and (ii) dividends from the Company Subsidiaries to it or any of its wholly owned Company Subsidiaries, provided that no such dividend shall cause any bank Company Subsidiary to cease to qualify as a “well capitalized”
institution under the prompt corrective action provisions of the Federal Deposit Insurance Corporation Improvement Act of 1991, as amended, and the applicable regulations thereunder; 
 (c) Directly or indirectly adjust, split, combine, redeem, reclassify, purchase or otherwise acquire, any shares of its stock (other than repurchases of
common shares in the ordinary course of business to satisfy obligations under dividend reinvestment or Company Employee Benefit Plans); 
  

 18 







 (d) Amend the terms of, waive any rights under, terminate, knowingly violate the terms of or enter into
(i) any Company Contract which is material to the Company or any Company Subsidiary, (ii) any material restriction on the ability of the Company or any Company Subsidiary to conduct its business as it is presently being conducted or
(iii) any contract or other binding obligation relating to the Company Common Stock or rights associated therewith or any other outstanding capital stock or any outstanding instrument of indebtedness; 
 (e) Sell, transfer, mortgage, encumber or otherwise dispose of or discontinue any of its assets, deposits, business or properties, except for sales,
transfers, mortgages, encumbrances or other dispositions or discontinuances in the ordinary course of business and in a transaction that, together with other such transactions, is not material to it or any Company Subsidiary; 
 (f) Acquire (other than by way of foreclosures or acquisitions of control in a fiduciary or similar capacity or in satisfaction of debts previously
contracted in good faith, in each case in the ordinary course of business) all or any portion of the assets, business, deposits or properties of any other entity except in the ordinary course of business and in a transaction that, together with
other such transactions, is not material to it or any Company Subsidiary, and does not present a material risk that the Closing Date will be materially delayed or that the regulatory approvals of Governmental Authorities required for the
consummation of the Transaction will be more difficult to obtain; 
 (g) Except for matters relating to any capital stock issued to the
United States Treasury as part of the TARP Capital Purchase Program or any similar governmental program, amend the Certificate of Incorporation or the Bylaws or similar governing documents of any of the Company Subsidiaries; 
 (h) Implement or adopt any change in its accounting principles, practices or methods, other than as may be required by GAAP or applicable regulatory
accounting requirements; 
 (i) Except as required under applicable law or, other than with respect to clause (v) below, the terms of
any Company Employee Benefit Plan existing as of the date hereof, (i) increase in any manner the compensation or benefits of any of the current or former directors, officers, employees, consultants, independent contractors or other service
providers of the Company or the Company Subsidiaries (collectively, “Employees”), (ii) pay any amounts to Employees or increase any amounts or rights of any Employees not required by any current plan or agreement,
(iii) become a party to, establish, amend, commence participation in, terminate or commit itself to the adoption of any stock option plan or other stock-based compensation plan, compensation, severance, pension, retirement, profit-sharing,
welfare benefit, or other employee benefit plan or agreement or employment agreement with or for the benefit of any Employee (or newly hired employees), (iv) accelerate the vesting of or lapsing of restrictions with respect to any stock-based
compensation or other long-term incentive compensation under any Company Employee Benefit Plans, (v) cause the funding of any rabbi trust or similar arrangement or take any action to fund or in any other way secure the payment of compensation
or benefits under any Company Employee Benefit Plan, or (vi) materially change any actuarial or other assumptions 

  

 19 







 
used to calculate funding obligations with respect to any Company Employee Benefit Plan or change the manner in which contributions to such plans are made or
the basis on which such contributions are determined, except as may be required by GAAP or applicable law; 
 (j) Notwithstanding anything
herein to the contrary, take, or omit to take, any action that is reasonably likely to result in any of the conditions to the Closing set forth in Article 8 not being satisfied, except as may be required by applicable law, regulation or policies
imposed by any Governmental Authority; 
 (k) Incur or guarantee any indebtedness for borrowed money other than in the ordinary course of
business; 
 (l) Take any action that would or could reasonably be expected to result in the Company’s disqualification from eligibility
to receive funds through the TARP Capital Purchase Program; or 
 (m) Agree to, or make any commitment to, take any of the actions prohibited
by this Section 5.2. 
 5.3 Access; Information. 
 (a) Prior to the Closing, the Company will (and will cause the Company Subsidiaries to): (i) afford, upon reasonable notice, to each Purchaser and
its representatives, counsel, accountants, agents and employees reasonable access to all of the Company’s and the Company Subsidiaries’ business, operations, properties, books, files and records, and will do everything reasonably necessary
to enable each Purchaser and its representatives, counsel, accountants, agents and employees to make a complete examination of the financial statements, business, assets and properties of the Company and the Company Subsidiaries and the condition
thereof and to update such examination at such intervals as such Purchaser shall deem appropriate, all upon reasonable notice and at such reasonable times and as often as such Purchaser may reasonably request; (ii) deliver to each Purchaser,
simultaneously with its delivery to the Company’s senior management, (A) the monthly financial reporting package delivered to the Company’s senior management and (B) any other periodic financial reports prepared by or on behalf
of the Company and the Company Subsidiaries for the senior management of the Company; (iii) make appropriate officers of the Company and Company Subsidiaries available upon reasonable notice and at such reasonable times and as often as
Purchasers may reasonably request for consultation with such Purchaser with respect to matters relating to the business and affairs of the Company and Company Subsidiaries; and (iv) to the extent consistent with applicable law, inform
Purchasers in advance (except with respect to events which require public disclosure, in which case only following the Company’s public disclosure thereof through applicable securities law filings or otherwise) with respect to any material
corporate actions and consult with the Company and Company Subsidiaries with respect to such actions, and consider, in good faith, the recommendations of Purchasers in connection with the matters on which they are consulted as described above,
recognizing that the ultimate discretion with respect to all such matters shall be retained by the Company. Notwithstanding the foregoing, at any time during which the Company is subject to the periodic reporting 

  

 20 







 
requirements of the Exchange Act or voluntarily reports thereunder, the Company may satisfy its obligations pursuant to clause (ii) by filing with the
SEC (via the EDGAR system or otherwise) annual and quarterly reports satisfying the requirements of the Exchange Act. Any investigation pursuant to this Section 5.3 shall be conducted in such manner as not to interfere unreasonably with the
conduct of the business of the Company, and nothing herein shall require the Company or any Company Subsidiary to disclose any information to the extent (x) prohibited by applicable law or regulation, (y) that the Company reasonably
believes such information to be competitively sensitive proprietary information (except to the extent Purchasers provide assurances reasonably acceptable to the Company that such information shall not be used by such Purchaser or its Affiliates to
compete with the Company and Company Subsidiaries), or (z) that such disclosure would reasonably be expected to cause a violation of any agreement to which the Company or any Company Subsidiary is a party or would cause a risk of a loss of
privilege to the Company or any Company Subsidiary (provided that the Company shall use commercially reasonable efforts to make appropriate substitute disclosure arrangements under circumstances where the restrictions in this clause (z)
apply). 
 (b) No investigation by Purchasers or its representatives shall affect the representations and warranties of the Company set forth
in this Agreement. 
 ARTICLE 6 
 Additional Agreements 
 6.1 Commercially Reasonable Best Efforts. Subject to the terms and conditions
of this Agreement, the Company and Purchasers agree to cooperate with the other and use their commercially reasonable best efforts in good faith to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary,
proper, desirable, or advisable on its part under this Agreement or under applicable laws to consummate and make effective the Transaction as promptly as practicable, including the satisfaction of the conditions set forth in Article 8 hereof.

 6.2 Press Releases. The initial press release issued by the Company and Purchasers concerning the Transaction and this
Agreement shall be a joint press release, and thereafter the Company and Purchasers shall consult with each other before issuing any press release with respect to the Transaction or this Agreement and shall not issue any such press release or make
any such public statements without the prior consent of the Required Purchasers or the Company, as the case may be, which consent shall not be unreasonably withheld or delayed; provided, however, that a party may, without the prior consent of
the Required Purchasers or the Company, as the case may be (but after such consultation, to the extent practicable in the circumstances), issue such press release or make such public statements as may upon the advice of outside counsel be required
by law or the rules or regulations of the NYSE or the SEC or any other applicable regulation. 
 6.3 Regulatory Approvals.
Without limiting the generality of Section 6.1, each Purchaser shall use its reasonable best efforts to prepare and file on behalf of it and any of its subsidiaries or Affiliates, and, to the extent necessary, the Company shall use its
reasonable best efforts to prepare and file on behalf of it or any Company Subsidiary or Affiliate, all documentation to effect all necessary notices, reports and other filings and to obtain all permits, 

  

 21 







 
consents, approvals and authorizations necessary or advisable to be obtained from any third parties and/or Governmental Authorities in order to consummate
the Transaction, and the Company shall reasonably cooperate with Purchasers in connection with the foregoing; and any initial filings with Governmental Authorities shall be made by Purchasers as soon as reasonably practicable after the date hereof.
TBW shall seek to obtain reasonable assurances from the OTS that Regulation W would not materially restrict existing dealings between TBW and Colonial Bank (“Regulation W Determination”). Subject to applicable laws relating to the
exchange of information, Purchasers and the Company shall have the right to review in advance, and to the extent practicable each shall consult with the other on, all material written information submitted to any third party and/or any Governmental
Authority in connection with the Transaction. In exercising the foregoing right, each of the parties agrees to act reasonably and as promptly as practicable. Each party hereto agrees that it shall to the extent legally permissible and practicable
consult with the other with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and/or Governmental Authorities necessary or advisable to consummate the Transaction and each party shall to
the extent legally permissible and practicable keep the other party apprised of the status of material matters relating to completion of the Transaction (including to the extent legally permissible and practicable (i) promptly furnishing the
other with copies of notices or other communications received by Purchasers or the Company, as the case may be, from any third party and/or Governmental Authority with respect to the Transaction and the establishment of any bank or thrift holding
company for purposes of the Transaction, and as otherwise contemplated by this Agreement and, to the extent permitted by law, and (ii) providing descriptions of any oral communications from such persons). Each party agrees, upon request, to
furnish the other party with all information concerning itself, its subsidiaries, directors, officers and stockholders or shareholders, as applicable, other than any information concerning each party’s officers, principals, directors and
stockholders or shareholders the disclosing party reasonably determines to be confidential, and such other matters as may be reasonably necessary or advisable in connection with any filing, notice or application made by or on behalf of such other
party to any third party and/or Governmental Authority. 
 6.4 NYSE Application; Amendment to Certificate of Incorporation.

 (a) As soon as practicable following the execution of this Agreement, the Company shall deliver to the NYSE, pursuant to Paragraph 312.05
of the NYSE Listed Company Manual, notice of and the requisite documents relating to the Company’s intent to issue the Shares without obtaining approval of the stockholders of the Company. No later than ten days after the date of this
Agreement, the Company shall mail to all stockholders, in compliance with said Paragraph 312.05, a letter alerting the stockholders to the Company’s omission to seek stockholder approval and that the Company’s Audit Committee has approved
such exception to the NYSE shareholder approval policy. Notwithstanding the foregoing, if, after the Company delivers such requisite Paragraph 312.05 notice and documentation to the NYSE, the NYSE rejects such application (other than a rejection
based on a technical defect in such application that is curable by the Company, in which case the Company shall cure such defect as soon as practicable after such notice from the NYSE), the Company shall comply with the covenant set forth in
Section 6.4(b) as soon as practicable after such rejection. 
  

 22 







 (b) Not later than three months after the Closing Date, the Company Board shall submit to its
stockholders for approval (the “Stockholder Approval”) an amendment to the Certificate of Incorporation (i) increasing the number of authorized shares of Company Common Stock so that there will be a sufficient number of
authorized shares of Company Common Stock to satisfy the conversion rights of all holders of the Shares and any other holders of the Company’s Preferred Stock having conversion rights, (ii) reducing the par value of the Company Common
Stock to $0.01 per share, and (iii) authorizing any amendments required by the TARP Capital Purchase Program or any similar governmental program. The Company Board shall recommend that the Company’s stockholders approve such amendment, and
will use all reasonable best efforts to obtain from the Company’s stockholders a vote approving and adopting such amendment. If the Stockholder Approval is not obtained within such three month period, the Company Board shall take all necessary
action in accordance with the DGCL to effectuate a reverse stock split to so increase the number of authorized shares of Company Common Stock. 
 6.5 No Solicitation. 
 (a) During the period from the date of this Agreement to the earlier of the Closing or the date
of termination of this Agreement, the Company agrees that it will not, and will cause the Company Subsidiaries and its and the Company Subsidiaries’ officers, directors, agents, advisors and affiliates not to, initiate, solicit, encourage or
knowingly facilitate inquiries or proposals with respect to, or engage in any negotiations concerning, or provide any confidential or nonpublic information or data to, or have any discussions with, any person relating to, any Acquisition Proposal.
The Company will immediately cease and cause to be terminated any activities, discussions or negotiations conducted before the date of this Agreement with any persons other than Purchasers with respect to any Acquisition Proposal and will use its
reasonable best efforts, subject to applicable law, to enforce any confidentiality or similar agreement relating to an Acquisition Proposal. 
 (b) Notwithstanding the foregoing Section 6.5(a), in the event that, at any time during the thirty (30) day period after the date of this Agreement, the Company receives an unsolicited Acquisition Proposal and the Company Board
concludes in good faith that there is a reasonable likelihood that such Acquisition Proposal constitutes or is reasonably likely to result in a Superior Proposal, the Company may, and may permit the Company Subsidiaries and its and the Company
Subsidiaries’ representatives to, furnish or cause to be furnished nonpublic information and participate in such negotiations or discussions to the extent that the Company Board concludes in good faith (and based on the advice of counsel) that
failure to take such actions would be reasonably likely to result in a violation of its fiduciary duties under applicable law; provided that prior to providing any nonpublic information permitted to be provided pursuant to the foregoing proviso, it
shall have entered into a confidentiality agreement with such third party on terms no less favorable to the Company than any confidentiality agreement entered into with Purchasers relating to the Transaction. The Company will promptly (and in any
event within two (2) Business Days) advise Purchasers following receipt of any Acquisition Proposal and the substance thereof (including the identity of the person making such Acquisition Proposal), and will keep Purchasers apprised of any
related developments, discussions and negotiations (including the terms and conditions of the Acquisition Proposal) on a current basis. 
  

 23 







 (c) The Company covenants that it will not accept, approve, endorse, recommend or enter into any
agreement, understanding or arrangement in respect of a Superior Proposal (other than a confidentiality agreement permitted by Section 6.5(b)) unless: 
 (i) The Company has complied with its obligations under Section 6.5(b) and has provided Purchasers with a copy of the Superior Proposal; and 
 (ii) A period (the “Response Period”) of five Business Days has elapsed from the date that is the later of (x) the date on which
Purchasers receive written notice from the Company Board that the Company Board has determined, subject only to compliance with this Section 6.5, to accept, approve, endorse, recommend or enter into a definitive agreement with respect to such
Superior Proposal, and (y) the date Purchasers receive a copy of the Superior Proposal. 
 (d) During the Response Period, Purchasers
will have the right, but not the obligation, to offer to amend this Agreement, including an increase in, or modification of, the Purchase Price. The Company Board shall review any such offer by Purchasers to amend this Agreement to determine whether
the Acquisition Proposal to which Purchasers are responding would continue to be a Superior Proposal when assessed against the Transaction as it is proposed in writing by Purchasers to be amended. If the Company Board determines that the Acquisition
Proposal no longer constitutes a Superior Proposal, the Company Board will cause the Company to enter into an amendment to this Agreement with Purchasers incorporating the amendments to this Agreement as set out in the written offer to amend. If the
Company Board determines that the Acquisition Proposal continues to be a Superior Proposal, the Company may accept such Superior Proposal and may terminate this Agreement pursuant to Section 9.1(f) in order to accept or enter into an agreement,
understanding or arrangement to proceed with the Superior Proposal, subject to Section 9.2. 
 (e) Each successive amendment to any
Acquisition Proposal that results in an increase in, or modification of, the consideration (or value of such consideration) to be received by the Company shall constitute a new Acquisition Proposal for the purposes of this Section 6.5 and
Purchasers shall be afforded a new Response Period and the rights afforded in this Section 6.5 in respect of each such Acquisition Proposal. 
 (f) As used in this Agreement, “Acquisition Proposal” means a tender or exchange offer, proposal for a merger, consolidation or other business combination involving Company or any of the Company Subsidiaries or any proposal
or offer to acquire in any manner more than fifteen percent (15%) of the voting power in, or more than fifteen percent (15%) of the fair market value of the business, assets or deposits of, the Company or any of the Company Subsidiaries,
other than the Transaction or any participation in (or application to participate in) the TARP Capital Purchase Program, the Capital Assistance Program or any similar governmental program. 
 (g) As used in this Agreement, “Superior Proposal” means a written Acquisition Proposal that the Company Board concludes in good faith
to be more favorable from a financial point of view to its stockholders than the Transaction, (i) after receiving the advice of 

  

 24 







 
its financial advisors (who shall be a nationally recognized investment banking firm), (ii) after taking into account the likelihood of consummation of
such transaction on the terms set forth therein and (iii) after taking into account all legal (with the advice of outside counsel), financial (including the financing terms of any such proposal), regulatory and other aspects of such proposal
and any other relevant factors permitted under applicable law; provided that for purposes of the definition of “Superior Proposal,” the references to “more than fifteen percent (15%)” in the definition of Acquisition
Proposal shall be deemed to be references to “a majority.” 
 6.6 Conversion Application. As soon as practicable
after the execution of this Agreement, the Company shall cause Colonial Bank to file an application with the OTS to convert from an Alabama state bank to a federally chartered savings and loan association, and the Company shall use its reasonable
best efforts to obtain the approval of such application from the OTS. As soon as practicable following the approval of such conversion by the OTS, the Company shall deregister as a bank holding company under the Bank Holding Company Act, as amended,
with the Federal Reserve. 
 6.7 Board Seats. 
 (a) On the Closing Date or as soon as practicable thereafter, the Company Board shall fix the number of directors at fifteen (15), of which five individuals, selected by Purchasers as representatives of Purchasers as
set forth below (the “Board Representatives”), shall be appointed to the Company Board and commence serving on the Company Board immediately thereafter, subject to satisfactory completion of a Directors & Officers
questionnaire and provision of other background information as may be reasonably requested by the Company, and subject to any required approvals of Regulatory Authorities. On the Closing Date or as soon as practicable thereafter, the Company shall
also cause two of the Board Representatives, at the option of the Required Purchasers, to be appointed to the Executive Committee of the Company Board (or any successor committee thereto). The Board Representatives shall be added to each class of
the Company Board as the Company and Purchasers shall mutually determine so that an approximately equal number of Board Representatives will be added to each class. Within sixty (60) days after the Closing Date, the Company shall cause the
Company Board’s composition to be as follows: (i) the five Board Representatives; (ii) five other continuing directors; and (iii) five other directors, mutually agreeable to the Company and Purchasers. On the Closing Date or as
soon as practicable thereafter, the Company shall cause Colonial Bank to fix the number of directors on the board of Colonial Bank at thirteen (13), and shall cause Colonial Bank to add the five Board Representatives to the Colonial Bank Board of
Directors as well. 
 (b) Regardless of the classes in which the Board Representatives have been placed, the Company shall include the Board
Representatives in the Company’s slate of director nominees recommended by the Company Board to be voted on by stockholders of the Company at the 2010 Annual Meeting of Stockholders (the “2010 Meeting”), subject to satisfaction
of all legal and governance requirements applicable to all board members regarding service as a director of the Company, including any applicable NYSE requirements. The Company shall also cause two Board Representatives to be re-appointed to the
Executive Committee of the Company Board (or any successor committee thereto). 
  

 25 







 (c) Through the 2010 Meeting and, assuming the Board Representatives are re-elected at the 2010 Meeting
by the stockholders of the Company, through the 2011 Annual Meeting of Stockholders, and consistent with any applicable rules of the NYSE, the Required Purchasers shall have the power to designate a replacement for a Board Representative upon the
death, resignation, retirement, disqualification or removal from office of such director, subject to satisfaction of all legal and governance requirements applicable to all board members regarding service as a director of the Company. 
 (d) Notwithstanding anything to the contrary set forth in this Section 6.7, at the time of the 2010 Meeting or the 2011 Annual Meeting of
Stockholders, as the case may be, (i) in the event that Purchasers hold, on an aggregate as-converted basis, less than fifty percent (50%) but greater than or equal to twenty-five percent (25%) of the number of Shares acquired by
Purchasers under this Agreement, then the Required Purchasers shall be entitled to appoint three Board Representatives and one member of the Executive Committee, and (ii) in the event that Purchasers hold, on an aggregate as-converted basis,
less than twenty-five percent (25%) of the number of Shares acquired by Purchasers under this Agreement, Purchasers shall not have the right under this Section 6.7 to appoint any Board Representatives or members of the Executive Committee.

 6.8 Preemptive Rights. 
 (a) If the Company offers to sell Covered Securities in a public or private offering of Covered Securities solely for cash (a “Qualified Offering”), each Purchaser shall be afforded the opportunity to acquire from the
Company, for the same price and on the same terms as such Covered Securities are offered, in the aggregate up to the amount of Covered Securities required to enable such Purchaser to maintain its then-current Purchaser Percentage Interest, but
solely to the extent that any such issuance of shares of Covered Securities would not result in the issuance of Covered Securities that would require a vote of the stockholders of the Company pursuant to the listing standards of the NYSE. As used in
this Section 6.8: (i) “Purchaser Percentage Interest” means, as of any date, the percentage equal to (A) the aggregate number of shares of Company Common Stock beneficially owned (with the term “beneficial
ownership” having the meaning ascribed in Section 13(d)(3) and Rule 13d-3 under the Exchange Act) or otherwise held by such Purchaser as of such date, calculated on an as-converted basis, divided by (B) the total number of outstanding
shares of Company Common Stock as of such date, calculated on an as-converted basis, provided that for purposes of calculating shares held by Purchasers in the foregoing subsections (A) and (B), in the event of any Qualified Offering
occurring prior to the Closing, Purchaser Percentage Interest will be calculated on a pro forma basis as if the Shares had been issued hereunder; and (ii) “Covered Securities” means Company Common Stock and any securities
convertible into or exercisable or exchangeable for Company Common Stock, other than securities that are (A) issued by the Company pursuant to any employment contract, employee or benefit plan, stock purchase plan, stock ownership plan, stock
option or equity compensation plan or other similar plan where stock is being issued or offered to a trust, other entity to or for the benefit of any employees, potential employees, consultants, officers or director of the Company, (B) issued
by the Company in connection with a business combination or other merger, acquisition or disposition transaction, (C) issued with reference to the Common Stock of a Subsidiary (i.e., a carve-out transaction), (D) issued as a dividend or in


  

 26 







 
connection with a dividend reinvestment or stockholder purchase plan, (E) issued in exchange for currently outstanding securities, or (F) issued to
the United States Treasury as part of the TARP Capital Purchase Program or any similar governmental program. 
 (b) Prior to making any
Qualified Offering of Covered Securities, the Company shall give each Purchaser written notice of its intention (including, in the case of a registered public offering and to the extent possible, a copy of the prospectus included in the registration
statement filed in respect of such), describing, to the extent then known, the anticipated amount of securities, price (or, in the case of a registered public offering, an estimated range of prices) and other material terms upon which the Company
proposes to offer the same. Such Purchaser shall have thirty (30) days from the provision of such notice to notify the Company in writing that it intends to exercise such preemptive purchase rights and as to the amount of Covered Securities
such Purchaser desires to purchase, up to the maximum amount calculated pursuant to Section 6.8(a) (the “Designated Securities”). Such notice shall constitute a non-binding indication of interest of such Purchaser to purchase
the amount of Designated Securities so specified (or a proportionately lesser amount if the amount of Covered Securities to be offered in such Qualified Offering is subsequently reduced) at the price (or range of prices) and other terms set forth in
the Company’s notice to it. The failure by such Purchaser to respond during such thirty (30) day period shall constitute a waiver of preemptive rights in respect of such offering. The obligation of the Company to provide such notice shall
be subject to such Purchaser’s written agreement to confidentiality and restrictions on trading terms reasonably acceptable to the Company. 
 (c) If a Purchaser exercises such Purchaser’s preemptive purchase rights provided in this Section 6.8 with respect to a Qualified Offering that is an underwritten public offering or a private offering made to qualified
institutional buyers (as such term is defined in Rule 144A under the Securities Act) for resale pursuant to Rule 144A under the Securities Act, the Company shall offer such Purchaser, if such underwritten public offering or Rule 144A offering is
consummated, the Designated Securities (as adjusted downward or, at such Purchaser’s option, upward to reflect the actual size of such offering when priced) at the same price as the Covered Securities are offered to the initial purchasers in
such offering and shall provide written notice of such price to such Purchaser as soon as practicable prior to such consummation. Contemporaneously with the execution of any underwriting agreement or purchase agreement entered into between the
Company and the underwriters or initial purchasers of such underwritten public offering or Rule 144A offering, such Purchaser shall, if it continues to wish to exercise its preemptive rights with respect to such offering, enter into an instrument in
form and substance reasonably satisfactory to the Company acknowledging such Purchaser’s binding obligation to purchase the Designated Securities to be acquired by it and containing representations, warranties and agreements of such Purchaser
that are customary in private placement transactions and, in any event, no less favorable to such Purchaser than any underwriting or purchase agreement entered into by the Company in connection with such offering, and the failure to enter into such
an instrument at or prior to such time shall constitute a waiver of preemptive rights in respect of such offering. Any offers and sales pursuant to this Section 6.8(c) in the context of a registered public offering shall also be conditioned on
reasonably acceptable representations and warranties of such Purchaser regarding its status as the type of offeree to whom a private sale can be made concurrently with a registered offering in compliance with applicable securities laws. 

 

 27 







 (d) If a Purchaser exercises its preemptive rights provided in this Section 6.8 with respect to a
Qualified Offering that is not an underwritten public offering or Rule 144A offering (a “Private Placement”), the closing of the purchase of the Covered Securities with respect to which such right has been exercised shall be
conditioned on the consummation of the Private Placement giving rise to such preemptive purchase rights and shall take place simultaneously with the closing of the Private Placement or on such other date as the Company and such Purchaser shall agree
in writing; provided that the actual amount of Covered Securities to be sold to such Purchaser pursuant to its exercise of preemptive rights hereunder shall be reduced if the aggregate amount of Covered Securities sold in the Private
Placement is reduced and, at the option of such Purchaser (to be exercised by delivery of written notice to the Company within five (5) Business Days of receipt of notice of such increase), shall be increased if such aggregate amount of Covered
Securities sold in the Private Placement is increased. In connection with its purchase of Designated Securities, such Purchaser shall, if it continues to wish to exercise its preemptive rights with respect to such offering, execute an agreement
containing representations, warranties and agreements of such Purchaser that are substantially similar in all material respects to the agreements executed by other purchasers in such Private Placement. 
 (e) If, prior to consummation of a Qualified Offering, the terms of the proposed issuance change with the result that the price is less than the minimum
price or more than the maximum price set forth in the notice contemplated by Section 6.8(b) or the other principal terms are more favorable in any material respect to the prospective purchaser than those set forth in such notice, it shall be
necessary for a separate notice to be furnished, and the terms and provisions of this Section 6.8 separately complied with. 
 (f)
Anything to the contrary in this Section 6.8 notwithstanding, the preemptive right to purchase Covered Securities granted by this Section 6.8 as to a Purchaser shall terminate as of and not be available for any offering that commences at
any time after the date on which such Purchaser offers, sells, pledges, or otherwise transfers any Shares purchased hereunder, including by way of entry into any swap or other agreement or transaction that hedges or transfers, in whole or in part,
directly or indirectly, the economic consequence of ownership of such Shares (a “Hedging Transaction”). 
 6.9
Restrictions on Transfer. For the period from the Closing Date until the date that is one year after the Closing Date, and subject to all applicable securities laws, no Purchaser shall, directly or indirectly, transfer, sell, assign,
pledge, convey, hypothecate or otherwise encumber or dispose of, or engage in a Hedging Transaction with respect to (collectively, “Transfer”) any of the Shares held by such Purchaser, other than: 
 (a) any Transfer by a Purchaser which, when taken together with any other Transfers of Shares by such Purchaser to the same person or any of its
Affiliates at any time, would cause all such Transfers to represent 9.9% or less of the aggregate outstanding shares of Company Common Stock and Preferred Stock, on an as-converted basis, as of immediately prior to such Transfer; 
  

 28 







 (b) Transfers with the consent of the Company Board (such consent not to be unreasonably withheld) to any
Affiliate of such Purchaser if the transferee agrees in writing for the benefit of the Company (with a copy thereof to be furnished to the Company and to be in form and substance reasonable satisfactory to the Company) to be bound by the terms of
this Agreement; and 
 (c) Transfers pursuant to a merger, tender offer or exchange offer or other business combination, acquisition of
assets or similar transaction or change of control involving the Company or any Company Subsidiary so long as such transaction has been approved by the Company Board and, if required, the stockholders of the Company. 
 6.10 Indemnity for Purchasers. The Company agrees to indemnify and hold harmless each Purchaser and its Affiliates and each of their
respective officers, directors, partners, members and employees, and each person who controls such Purchaser within the meaning of the Exchange Act and the rules and regulations promulgated thereunder (each an “Indemnified Person”),
to the fullest extent lawful, from and against any and all judgments, fines, amounts paid in settlement and expenses (including reasonable attorneys’ fees and disbursements) (collectively, “Losses”) arising out of or resulting
from any action, suit, claim, proceeding or investigation by any Governmental Authority, stockholder of the Company or any other person (other than the Company or Purchasers) relating to this Agreement or the Transaction (other than any Losses
attributable to the acts, errors or omissions on the part of such Purchaser, but not including the Transaction) within eighteen (18) months of the Closing Date; provided, that nothing herein shall be deemed to preclude an Indemnified
Person from making an indemnification claim after such eighteen (18) month period with respect to Losses arising during such eighteen (18) month period. With respect to any Losses in respect of which indemnity may be sought under this
Section 6.10, the respective rights and obligations and procedures contained in Section 7.9 shall apply as if restated in this Section 6.10. In the event Purchasers receive payment in connection with Section 9.2, any and all
obligations of the Company pursuant to this Section 6.10 shall terminate immediately. 
 6.11 Change in Control
Agreements. Simultaneously with or prior to the execution of this Agreement, the Company shall deliver or cause to be delivered fully executed amendments, consents or waivers to existing employment agreements, change in control
agreements and agreements regarding Company Stock Options and grants of restricted stock with employees of the Company, designated by Purchasers, in form and substance satisfactory to Purchasers, providing that the Transaction shall not constitute a
change in control under such agreements or awards. Following the execution of this Agreement, upon the reasonable request of the Required Purchasers, the Company shall use its reasonable best efforts to cause its employees subject to The Colonial
BancGroup, Inc. Restated 2001 Long-Term Incentive Plan or any other applicable Company Employee Benefit Plan to execute amendments, consents or waivers providing that the Transaction shall not constitute a change in control under such Company
Employee Benefit Plans. 
  

 29 







 ARTICLE 7 
 Private Placement of the Shares; Registration Rights 
 7.1 Securities Act
Exemption. 
 (a) It is intended that the Shares to be issued pursuant to this Agreement will not be registered under the Securities
Act in reliance on the exemption from the registration requirements of Section 5 of the Securities Act set forth in Section 4(2) and Regulation D under the Securities Act. 
 (b) Each Purchaser agrees that all certificates or other instruments representing Shares of Series A Stock will bear a legend substantially to the
following effect: 
 “THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER SUCH ACT OR SUCH LAWS. THIS INSTRUMENT IS ISSUED PURSUANT TO AND SUBJECT TO THE RESTRICTIONS ON TRANSFER AND OTHER PROVISIONS OF A STOCK PURCHASE AGREEMENT, DATED AS OF MARCH 31, 2009, BETWEEN THE ISSUER OF THESE SECURITIES
AND PURCHASERS REFERRED TO THEREIN, A COPY OF WHICH IS ON FILE WITH THE ISSUER. THE SECURITIES REPRESENTED BY THIS INSTRUMENT MAY NOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH SAID AGREEMENT. ANY SALE OR OTHER TRANSFER NOT IN
COMPLIANCE WITH SAID AGREEMENT WILL BE VOID.” 
 TBW agrees that all certificates or other instruments representing Shares of Series B Stock will bear a
legend substantially to the following effect: 
 “THE SHARES OF PREFERENCE STOCK REPRESENTED BY THIS CERTIFICATE ARE NOT SAVINGS
ACCOUNTS, DEPOSITS OR OTHER OBLIGATIONS OF A BANK AND ARE NOT INSURED BY THE FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER GOVERNMENTAL AGENCY. 
 THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION
STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR 

  

 30 







 
PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR SUCH LAWS. THIS INSTRUMENT IS ISSUED PURSUANT TO AND SUBJECT TO THE RESTRICTIONS ON TRANSFER AND
OTHER PROVISIONS OF A STOCK PURCHASE AGREEMENT, DATED AS OF MARCH 31, 2009, BETWEEN THE ISSUER OF THESE SECURITIES AND PURCHASERS REFERRED TO THEREIN, A COPY OF WHICH IS ON FILE WITH THE ISSUER. THE SECURITIES REPRESENTED BY THIS INSTRUMENT MAY NOT
BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH SAID AGREEMENT. ANY SALE OR OTHER TRANSFER NOT IN COMPLIANCE WITH SAID AGREEMENT WILL BE VOID. 
 INSOFAR AS THE SHARES OF PREFERENCE STOCK REPRESENTED BY THIS CERTIFICATE ARE HELD BY TAYLOR, BEAN & WHITAKER MORTGAGE CORP. OR ANY OF ITS AFFILIATES, THE SHARES OF PREFERENCE STOCK REPRESENTED BY THIS
CERTIFICATE MAY NOT BE CONVERTED TO COMMON STOCK OF THE ISSUER UNLESS (1) THE AMOUNT OF COMMON STOCK AFTER CONVERSION HELD BY TAYLOR, BEAN & WHITAKER MORTGAGE CORP. OR ANY OF ITS AFFILIATES WOULD BE LESS THAN 25% OF THE OUTSTANDING
NUMBER OF SHARES OF COMMON STOCK OF THE ISSUER FOLLOWING CONVERSION, OR (2) THE CONVERSION IS COMPLETED ONLY IN CONNECTION WITH: (A) A WIDELY DISPERSED PUBLIC OFFERING; (B) PRIVATE SALES IN WHICH NO PURCHASER OR GROUP OF PURCHASERS
WOULD ACQUIRE MORE THAN 2% OF THE NUMBER OF SHARES OF ISSUER STOCK OUTSTANDING FOLLOWING THE CONVERSION; (C) SALES TO THE ISSUER; OR (D) SALES TO A PARTY THAT IS UNAFFILIATED WITH TAYLOR, BEAN & WHITAKER MORTGAGE CORP. OR ANY OF
ITS AFFILIATES THAT IS ACQUIRING MAJORITY CONTROL OF THE ISSUER.” 
 (c) In the event that any Shares (i) are no longer subject to
the transfer restrictions set forth in this Agreement, (ii) are Transferred in a transaction registered under the Securities Act, (iii) are Transferred in a transaction exempt from the registration requirements of the Securities Act, and
upon delivery to the Company of such documents as it may reasonably request with respect to such exemption, or (iv) upon a Purchaser’s request and receipt by the Company and its transfer agent of an opinion of such Purchaser’s
counsel, reasonably satisfactory to the Company and its transfer agent, to the effect that a “private placement” legend is no longer required under the Act and applicable state laws, the Company shall issue new certificates representing
such Shares, which shall not contain such portion of the above legend that is no longer applicable. Each Purchaser acknowledges that the Shares have not been registered under the Securities Act or under any state securities laws and agrees that it
will not sell or otherwise dispose of the Shares, except in compliance with the registration requirements or exemption provisions of the Securities Act and any other applicable securities laws. 
  

 31 







 7.2 Definitions. For purposes of this Article 7, the following capitalized terms have the
following meanings: 
 “Person”: Any individual, partnership, limited liability company, joint venture, corporation,
association, trust or any other entity or organization. 
 “Registrable Securities”: The shares of Company Common Stock into
which the Shares are convertible, together with any other securities which a Purchaser may acquire on account of any the Shares, including, without limitation, as the result of any dividend or other distribution on the Company Common Stock or any
split-up of the Company Common Stock or in connection with any combination of shares, recapitalization, merger, consolidation or reorganization or otherwise. 
 “Registration Statement”: Any registration statement of the Company under the Securities Act that covers any of the Registrable Securities pursuant to the provisions of this Agreement, including the
related prospectus, any preliminary prospectus, all amendments and supplements to such registration statement (including post-effective amendments), all exhibits and all material incorporated by reference or deemed to be incorporated by reference in
such registration statement. 
 “Underwritten Offering”: A distribution, registered pursuant to the Securities Act, in which
securities of the Company are sold to the public through one or more underwriters. 
 7.3 Demand Registration. 
 (a) Requests for Registration. At any time commencing on or after the date that is 270 days following the Closing Date, the Required Purchasers
will have the right, by written notice delivered to the Company (a “Demand Notice”), to require the Company to register Registrable Securities under and in accordance with the provisions of the Securities Act (a “Demand
Registration”); provided that (i) Purchasers may not make more than three Demand Registrations, and (ii) the Purchasers desiring to participate in the offering must provide to the Company a certificate (the
“Authorizing Certificate”) signed by the participating Purchasers; and provided, further, that no Demand Notice may be given prior to six months after the effective date of the immediately preceding Demand
Registration. For purposes of the preceding sentence, the filing of two or more Registration Statements in response to one demand shall be counted as one Demand Registration. Each request for a Demand Registration by the Purchasers shall state the
amount of the Registrable Securities proposed to be sold and the intended method of disposition thereof. The Authorizing Certificate shall set forth (A) the name of each participating Purchaser signing such Authorizing Certificate, (B) the
number of Registrable Securities held by each participating Purchaser and the number of Registrable Securities each participating Purchaser has elected to have registered, and (C) the intended methods of disposition of the Registrable
Securities. Any participating Purchaser may at its option withdraw Registrable Securities from a registration and, in such event (l) any continuing registration of Registrable Securities shall constitute the Demand Registration to which the
Purchasers are entitled and (2) the withdrawing participating Purchaser shall reimburse the Company for any registration and filing fees (including any fees payable to the SEC) it has incurred with respect to 

  

 32 







 
the withdrawn Registrable Securities (unless all Registrable Securities are withdrawn, in which case the withdrawing Purchasers shall reimburse the Company
for all costs and expenses incurred by it in connection with the registration of such Registrable Securities). Subject to compliance with clause (2) of the preceding sentence, a registration that is terminated in its entirety prior to the
effective date of the applicable Registration Statement will not constitute a Demand Registration. Notwithstanding the foregoing, if at the time of withdrawal, a participating Purchaser has learned of a material adverse change in the condition,
business or prospects of the Company and has withdrawn the request with reasonable promptness following disclosure by the Company, such participating Purchaser shall not be subject to clause (2) above. 
 If a Demand Registration is not declared and maintained effective for the period required by Section 7.3(b) or if the consummation of the offering
of Registrable Securities pursuant to such Demand Registration (A) is interfered with by any stop order, injunction or other order or requirement of the SEC or other governmental agency or court for any Person which is not directly caused by
the act or omission of any Purchaser and such act or omission is not thereafter eliminated or (B) the conditions specified in the underwriting agreement with respect to an Underwritten Offering, if any, entered into in connection with such
Demand Registration are not satisfied or waived, other than by reason of a failure by a participating Purchaser, then the Purchasers shall be entitled to an additional Demand Registration in lieu thereof. 
 (b) Filing and Effectiveness. 
 (i)
The Company will file a Registration Statement relating to any Demand Registration as promptly as practicable (but in any event within 45 days in the case of a registration made on Form S-1, or a comparable successor form, as applicable, or 30 days
in the case of any registration eligible to be made on Form S-3 or a comparable successor form, as applicable) following the date on which the Demand Notice is given and will use its reasonable best efforts to cause the same to be declared effective
by the SEC as soon as practicable thereafter (the “Effectiveness Date”). 
 (ii) The Company agrees to use its reasonable
best efforts to comply with all necessary provisions of the federal securities laws in order to keep each Registration Statement relating to a Demand Registration effective for a period of (A) in the case of an Underwritten Offering, 120 days
from its Effectiveness Date, and (B) in the case of any registration made pursuant to Rule 415 under the Securities Act, when all Registrable Securities covered by such Registration Statement have been sold pursuant to such Registration
Statement (in each case, such period being the “Effectiveness Period”); provided, however, that if a delay, suspension or withdrawal under Section 7.6 hereof occurs during an Effectiveness Period, then such Effectiveness
Period will be tolled for the duration of such delay, suspension or withdrawal. 
 (iii) A Purchaser participating in a Registration
Statement will be permitted, subject to its compliance with the provisions of Section 7.3(a) relating to reimbursement of the Company’s expenses, to withdraw in good faith all or part of the Registrable Securities from a Demand
Registration at any time prior to the effective date of such Demand Registration, in which event the Company will promptly amend or, if applicable, withdraw the related Registration Statement. 
  

 33 







 (c) Priority on Demand Registration. Notwithstanding the foregoing, if the managing underwriter or
underwriters of an Underwritten Offering to which such Demand Registration relates advises the Company and the participating Purchasers in writing that the total amount of Registrable Securities that the participating Purchasers, the Company and any
other Person intend to include in such Demand Registration is in the aggregate such as to materially and adversely affect the success of such offering, then there will be included in such Demand Registration, (i) first, the number of securities
that the Purchasers propose to sell pursuant to such Demand Registration and the number of securities, determined pro rata on the basis of the number of Shares owned by each participating Purchaser, (ii) second, to the extent that the
number of securities in clause (i) above is less than the number of securities which the Company and Purchasers have been advised can be sold in such offering without having the adverse effect referred to above, the securities, if any, sought
to be included by the Company in the offering, and (iii) third, to the extent that the number of securities in clauses (i) and (ii) above is less than the number of securities which the Company and the Purchasers have been advised can
be sold in such offering without having the adverse effect referred to above, the number of securities, if any, requested to be included in such offering by any other Persons pursuant to similar registration rights, determined pro rata on the
basis of the number of shares of the class being sold owned by such other Persons requesting registration, collectively. 
 7.4
Piggyback Registration. 
 (a) Right to Piggyback. If, at any time following the Closing Date, the Company proposes to
file a Registration Statement, whether or not for sale for the Company’s own account or for the account of a stockholder of the Company, on a form and in a manner that would also permit registration, offer or sale of Registrable Securities
(other than in connection with a registration statement on Forms S-4 or S-8 or any similar or successor forms), the Company shall each such time give to the Purchasers holding Registrable Securities written notice of such proposed filing at least 20
days before the anticipated filing. The notice referred to in the preceding sentence shall (i) describe the proposed registration and offering and (ii) offer Purchasers the opportunity to register, offer or sell such amount of Registrable
Securities as Purchasers may request (a “Piggyback Registration”). Subject to Section 7.4(b), the Company will include in each such Piggyback Registration (and any related qualification under state blue sky laws and other
compliance filings, and in any underwriting involved therein) all Registrable Securities with respect to which the Company has received written requests for inclusion therein within 10 days after the written notice from the Company is given. Each
Purchaser will be permitted, subject to its compliance with the provisions of Section 7.3(a) relating to reimbursement of the Company’s expenses, to withdraw all or part of its Registrable Securities from a Piggyback Registration at any
time prior to the effective date of such Piggyback Registration. 
 (b) Priority on Piggyback Registrations. The Company will cause
the managing underwriter or underwriters of a proposed Underwritten Offering to permit the participating Purchasers, if holding Registrable Securities requested to be included in the 

  

 34 







 
registration for such offering, to include therein all such Registrable Securities requested to be so included (such securities, together with any other
shares of the same class requested to be included in such registration by any other Person pursuant to similar registration rights, the “Piggyback Shares”) on the same terms and conditions as any securities of the Company included
therein (other than the indemnification by participating Purchasers, which will be limited as set forth in Section 7.8(b) hereof and provided, that such Purchasers give customary representations and warranties). The Company shall
cooperate with the Purchasers in order to limit any representations and warranties to, or agreements with, the Company or the underwriters to be made by the Purchasers only to those representations, warranties or agreements regarding the
participating Purchasers, their Registrable Securities and their intended method of distribution and any other representation required by law. 
 Notwithstanding the foregoing, if the managing underwriter or underwriters of such Underwritten Offering advises Purchasers in writing to the effect that the total amount of securities that Purchasers, the Company and any other Person
propose to include in such Underwritten Offering is such as to materially and adversely affect the success of such offering, then the Company will include in such registration: 
 (i) in the case of a registration in connection with a sale of securities for the Company’s own account, (A) first, 100% of the securities that
the Company proposes to sell for its own account, (B) second, to the extent that the number of securities in clause (A) above is less than the number of securities which the Company has been advised can be sold in such offering without
having the adverse effect referred to above, the number of Piggyback Shares of the Purchasers, determined pro rata on the basis of the number of Shares owned by the Purchasers, and (C) third, to the extent that the number of securities
in clauses (A) and (B) above is less than the number of securities which the Company has been advised can be sold in such offering without having the adverse effect referred to above, the number of Piggyback Shares requested to be included
in such offering by any other Persons pursuant to similar registration rights, determined pro rata on the basis of the number of shares of the class being sold owned by such other Persons requesting registration, collectively; and 

(ii) in the case of a registration in connection with a sale of securities on account of any Person other than the Company (the “Initiating
Party”), (A) first, 100% of the securities, if any, that the Initiating Party proposes to sell, (B) second, to the extent that the number of securities in clause (A) above is less than the number of securities which the
Company has been advised can be sold in such offering without having the adverse effect referred to above, the number of Piggyback Shares of the participating Purchasers, determined pro rata on the basis of the number of Shares then owned by
those Purchasers wishing to participate, (C) third, to the extent that the number of securities in clauses (A) and (B) above is less than the number of securities which the Company has been advised can be sold in such offering without
having the adverse effect referred to above, the number of Piggyback Shares requested to be included in such offering by any other Persons pursuant to similar registration rights, determined pro rata on the basis of the number of shares of
the class being sold owned by such other Persons requesting registration, collectively, and (D) fourth, to the extent that the number of securities in clauses (A) through (C) above is less than the number of securities which the
Company has been advised can be sold in such offering without laving the adverse effect referred to above, the securities sought to be included by the Company in the offering. 
  

 35 







 7.5 Certain Registration Procedures. In connection with a Registration Statement to be
filed by the Company pursuant to this Agreement: 
 (a) Each Purchaser agrees to provide in a timely manner information requested by the
Company regarding the proposed distribution by such Purchaser of the Registrable Securities and all other information reasonably requested by the Company in connection with the preparation of such Registration Statement. 
 (b) The Company will prepare and file with the SEC such amendments and supplements to a Registration Statement and the prospectus or prospectus
supplement used in connection therewith as may be necessary (i) to keep such Registration Statement effective and usable for resale of the Registrable Securities during the Effectiveness Period, including by refiling a Registration Statement
(or a new Registration Statement) if the initial Registration Statement expires, and (ii) to comply with the provisions of the Securities Act with respect to the disposition of the securities covered by such registration statement, in each case
for such time as is contemplated by this Article 7. In the event that the Company is a well-known seasoned issuer (as defined under Rule 405 of the Securities Act) at the time of the filing of a Registration Statement with the SEC, such Registration
Statement shall be designated by the Company as an automatic Registration Statement. 
 (c) The Company will furnish to Purchasers such
number of copies of the applicable Registration Statement and each such amendment and supplement thereto (including in each case all exhibits) and of a prospectus, including a preliminary prospectus, in conformity with the requirements of the
Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned or to be distributed by them. 
 (d) The Company shall use its reasonable best efforts to register and qualify the securities covered by each Registration Statement under such other
securities or “blue sky” laws of such jurisdictions as shall be reasonably requested by Purchasers, to keep such registration or qualification in effect for so long as such Registration Statement remains in effect, and to take any other
action which may be reasonably necessary to enable each Purchaser to consummate the disposition in such jurisdictions of the Registrable Securities covered by such Registration Statement that are owned by such Purchaser; provided that the
Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; 
 (e) After the filing of a Registration Statement, the Company will promptly notify Purchasers of any stop order issued or threatened by the SEC and shall
take all commercially reasonable actions required to prevent the entry of such stop order or to remove it if entered. 
  

 36 







 (f) The Company shall cause the Registrable Securities to be listed on each securities exchange on which
Company Common Stock is then listed. 
 (g) The Company shall promptly notify Purchaser: 
 (i) at any time when a prospectus relating to a Registration Statement is required to be delivered under the Securities Act, of the existence of any fact
of which the Company is aware or the occurrence of an event requiring the preparation of a supplement or amendment to either a Registration Statement or related prospectus so that, as thereafter delivered to the purchasers of the Registrable
Securities, such Registration Statement or related prospectus, both as then in effect, will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statement
therein, in light of the circumstances then existing, not misleading and promptly make available to each Purchaser a reasonable number of copies of any such supplement or amendment; 
 (ii) when any Registration Statement filed pursuant to this Article 7 or any amendment thereto (other than through the incorporation by reference
therein of any report, statement or other document required to be filed pursuant to the Exchange Act and the rules and regulations thereunder) has been filed with the SEC and when such Registration Statement or any post-effective amendment thereto
has become effective; and 
 (iii) of any request by the SEC for amendments or supplements to any Registration Statement or the prospectus
included therein; and 
 (iv) of the receipt by the Company or its legal counsel of any notification with respect to the suspension of the
qualification of the Company Common Stock for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose. 
 (h) The Company shall use commercially reasonable efforts to procure the cooperation of the Company’s transfer agent in settling any offering or sale of Registrable Securities, including with respect to the transfer of physical stock
certificates into book-entry form in accordance with any procedures reasonably requested by a Purchaser. 
 (i) The Company will enter into
such customary agreements (including, in the event of an Underwritten Offering, an underwriting agreement in form, scope and substance as is customary in underwritten offerings) and take all such other commercially reasonable and customary actions
in connection therewith (including those reasonably requested by the Purchasers or, in the event of an Underwritten Offering, those reasonably requested by the managing underwriters) in order to facilitate the disposition of such Registrable
Securities and in such connection, but only where an underwriting agreement is entered into in connection with an Underwritten Offering: (i) make such representations and warranties to the underwriters with respect to the businesses of the
Company and its subsidiaries, the Registration Statement, prospectus and documents incorporated by reference or deemed incorporated by reference therein, if any, in each case, in form, substance and scope as are customarily made by issuers to
underwriters in underwritten offerings and confirm the same if and when requested; (ii) obtain opinions of counsel to the Company and updates thereof, which counsel and opinions (in form, 

  

 37 







 
scope and substance) shall be reasonably satisfactory to the managing underwriters, if any, addressed to each of the underwriters covering the matters
customarily covered in opinions requested in underwritten offerings and such other matters as may be reasonably requested by such underwriters; (iii) obtain “comfort” letters and updates thereof from the independent certified public
accountants of the Company (and, if necessary, any other certified public accountants of any subsidiary of the Company or of any business acquired by the Company for which financial statements and financial data is, or is required to be, included in
the Registration Statement), addressed to each of the underwriters, such letters to be in customary form and covering matters of the type customarily covered in “comfort” letters in connection with underwritten offerings; (iv) cause
the Company’s management to be made available for, and assist in, the marketing and disposition of such Registrable Securities in the manner and to the extent reasonably requested by the underwriters including, without limitation, participation
by management in customary road shows, investor conferences and other similar presentations; and (v) deliver such documents and certificates as may be reasonably requested by the managing underwriters, if any, to evidence the continued validity
of the representations and warranties of the Company and its subsidiaries made pursuant to clause (i) above and to evidence compliance with any customary conditions contained in the underwriting agreement entered into by the Company. The
foregoing actions will be taken in connection with each closing under such underwriting agreement as and to the extent required thereunder. 
 (j) All Registration Expenses incurred in connection with a Registration Statement hereunder shall be borne by the Company. “Registration Expenses” means the following expenses incurred by the Company in effecting any
registration pursuant to this Agreement (whether or not any registration or prospectus becomes effective or final): all registration fees, fees and disbursements of counsel for the Company, blue sky filing fees, printing expenses, and expenses of
the Company’s independent accountants in connection with any regular or special reviews incident to or required by such registration, and fees and disbursements of counsel for Purchaser. For the avoidance of doubt, the Company shall not be
responsible for and shall not pay any underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of Registrable Securities. 
 (k) If any of the Registrable Securities included in any Demand Registration are to be sold in an Underwritten Offering, the participating Purchasers may select an investment banking firm or firms to manage the
Underwritten Offering, provided that such investment banker or bankers is (are) reasonably acceptable to the Company. The Company and the participating Purchasers agree that, in connection with any Underwritten Offering hereunder, the relevant
registration shall be in a firm commitment underwritten offering and they shall each undertake to offer customary indemnification, representations and warranties to the participating underwriters and to agree to any restrictions required by the
underwriters on the sale of Company Common Stock or other securities by such party after the completion of the Underwritten Offering; provided, however, that the restriction so imposed on the participating Purchasers shall be no more onerous
than the restrictions imposed on any other holder of securities included in such offering; and provided, further that the Company shall not be required to agree to (i) restrictions with respect to the issuance of equity incentives to employees,
the issuance of securities on exercise of outstanding warrants or convertible securities, the issuance of securities in connection with a merger, acquisition, joint venture or other strategic transaction, or (ii) any 

  

 38 







 
restrictions that extend beyond the restrictions imposed on Purchaser for a term of ninety (90) days (one hundred eighty (180) days for an initial
public offering) from the effective date of the applicable Registration Statement. Without limiting the generality of the foregoing, before Registrable Securities shall be included in any Demand Registration, the participating Purchasers and any
underwriter acting on their behalf shall have agreed to indemnify and hold harmless the Company, each director of the Company, each officer of the Company who shall sign such registration statement and any person who controls the Company within the
meaning of the Securities Act, with respect to any statement or omission from such registration statement, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereto, if such statement or omission was
made in reliance upon and in conformity with written information furnished to the Company through an instrument duly executed by such Purchaser or underwriter specifically for use in the preparation of such registration statement, preliminary
prospectus, final prospectus or amendment or supplement. 
 (l) All obligations of the Company and Purchasers in this Article 7 (other than
as set forth in Sections 7.7, 7.8, 7.9 and 7.10) shall terminate and be of no further force and effect with respect to any Registrable Securities once (i) they are sold pursuant to an effective registration statement under the Securities Act,
(ii) they may be sold pursuant to Rule 144 of the Securities Act without limitation thereunder on volume or manner of sale, or (iii) they shall have ceased to be outstanding. 
 7.6 Material Developments; Suspension of Offering. 
 (a) Notwithstanding the provisions of Sections 7.3 or 7.4 hereof or any other provisions of this Agreement to the contrary, the Company shall not be required to file a Registration Statement or to keep a Registration
Statement effective if the negotiation or consummation of a transaction by the Company or any Company Subsidiary or Affiliates is pending or an event has occurred, which negotiation, consummation or event would require additional disclosure by the
Company in a Registration Statement of material information which the Company in its reasonable judgment has a bona fide business purpose for keeping confidential and the nondisclosure of which in a Registration Statement would be expected, in the
Company’s reasonable determination, to cause a Registration Statement or any prospectus filed with respect thereto or included therein to fail to comply with applicable disclosure requirements; provided, however, that the Company
(i) will promptly notify Purchasers of a delay, suspension or withdrawal pursuant to this Section 7.6 (without having to provide details thereof) and (ii) may not delay, suspend or withdraw a Registration Statement for such reason
under this Section 7.6 more than four (4) times in any twelve (12) month period and in no event for more than one hundred and twenty (120) days during the same such twelve (12) month period. Upon receipt of any notice from
the Company of the happening of any event during the period when a Registration Statement is effective which is of a type specified in the preceding sentence or as a result of which a Registration Statement or related prospectus contains any untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statement therein, in light of the circumstances under which they were made, not misleading, Purchasers will immediately
discontinue offers and sales of the Registrable Securities under a Registration Statement (until Purchasers have received copies of a supplemental or amended prospectus or prospectus supplement that corrects the misstatements or 

  

 39 







 
omissions and received notice that any post-effective amendment has become effective or unless notified by the Company that Purchasers may resume such offers
and sales). If so directed by the Company, each Purchaser will use its reasonable best efforts to deliver to the Company any copies of the prospectus, other than permanent file copies then in Purchaser’s possession, covering the Registrable
Securities in its possession at the time of receipt of such notice. Except as required by law, each Purchaser agrees to keep confidential the fact that the Company has exercised its rights under this Section 7.6 and all facts and circumstances
relating to such exercise until such information is made public by the Company. 
 (b) If all reports required to be filed by the Company
pursuant to the Exchange Act have not been filed by the required date without regard to any extension, or if the consummation of any business combination by the Company has occurred or is probable for purposes of Rule 3-05 or Article 11 of
Regulation S-X under the Securities Act, upon written notice thereof by the Company to Purchasers, the rights of Purchasers to offer, sell or distribute any Registrable Securities pursuant to a Registration Statement or to require the Company to
take action with respect to a Registration Statement pursuant to this Agreement shall be suspended until the date on which the Company has filed such reports or obtained and filed the financial information required by Rule 3-05 or Article 11 of
Regulation S-X to be included or incorporated by reference, as applicable, in such Registration Statement and the Company shall notify Purchasers as promptly as practicable when such suspension is no longer required; provided, that the rights
of Purchasers shall not be suspended pursuant to the preceding clause more than four (4) times in any twelve (12) month period and in no event for more than one hundred and twenty (120) days during the same such twelve (12) month
period. The Company’s rights to suspend its obligations under this Section 7.6(b) shall be in addition to its rights under Section 7.6(a). 
 7.7 Indemnification by the Company. The Company agrees to indemnify and hold harmless each Purchaser and, as applicable, its Affiliates, partners, members, officers, directors, employees,
representatives, and agents, and each person, if any, who controls such Purchaser within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act from and against any and all losses, claims, actions, damages,
liabilities, costs and expenses (including reasonable fees, expenses and disbursements of attorneys and other professionals incurred in connection with investigating, defending, settling, compromising or paying any such losses, claims, actions,
damages, liabilities, costs and expenses) caused by: 
 (a) any untrue statement or alleged untrue statement of a material fact contained in a
Registration Statement (or any amendment thereto), including any preliminary prospectus or final prospectus contained therein or any amendment or supplement thereto, or any documents incorporated therein by reference (collectively, the
“Registration Statement Filings”), or 
 (b) the omission or alleged omission to state in a Registration Statement Filings a
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or 
  

 40 







 (c) arising out of any untrue statement or alleged untrue statement of a material fact contained in any
preliminary or final prospectus (or any amendment or supplement thereto) or any documents incorporated therein by reference or contained in a Registration Statement at the time it became effective (a “Resale Prospectus”), including
any preliminary or final prospectus contained therein or any amendment or supplement thereto, or any documents incorporated therein by reference, or 
 (d) the omission or alleged omission therefrom of a material fact necessary in order to make the statements in the Resale Prospectus, in light of the circumstances under which they were made, not misleading, except
insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information furnished in writing to the Company by a Purchaser or on such Purchaser’s
behalf expressly for inclusion therein; provided, however, that the Company will not be liable in any case to the extent that any such claim, loss, damage, liability or expense arises out of or is based upon any untrue statement or
omission contained in a Resale Prospectus which was corrected in a supplement or amendment thereto if such claim is brought by a purchaser of the Registrable Securities from a Purchaser and such Purchaser failed to deliver to such purchaser the
supplement or amendment to the Resale Prospectus in a timely manner. 
 7.8 Indemnification by Purchasers. Each Purchaser,
severally and not jointly, agrees to indemnify and hold harmless the Company, its officers, directors and agents and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20
of the Exchange Act to the same extent as the indemnity set forth in Section 7.7 from the Company to Purchasers, but only with respect to information relating to such Purchaser furnished in writing by such Purchaser or on such Purchaser’s
behalf expressly for use in a Registration Statement or Resale Prospectus or any amendment or supplement thereto. 
 7.9 Conduct of
Indemnification Proceedings. 
 (a) Each indemnified party shall give prompt written notice to each indemnifying party of any claim,
action, suit or proceeding commenced against it (each a “Claim”) in respect of which indemnity may be sought hereunder, but failure to so notify the indemnifying party (i) shall not relieve it from any liability which it may
have under the indemnity agreement provided in Section 7.7 or 7.8 above, unless and to the extent the indemnifying party shall have been actually prejudiced by the failure of such indemnified party to so notify such party and (ii) shall
not, in any event, relieve the indemnifying party from any obligations to the indemnified party other than the indemnification obligation provided under Section 7.7 or 7.8 above. Such notice shall describe in reasonable detail such Claim.

 (b) In case any Claim is brought against an indemnified party, the indemnified party shall be entitled to hire, at its own expense,
separate counsel and participate in the defense thereof. If the indemnifying party so elects within a reasonable time after receipt of notice, the indemnifying party may assume the defense of the action or proceeding at the indemnifying party’s
own expense with counsel chosen by the indemnifying party and approved by the indemnified party, which approval shall not be unreasonably withheld; provided, however, that 

  

 41 







 
the indemnifying party will not settle or compromise any Claim, or consent to the entry of any judgment with respect to any such pending or threatened Claim,
without the written consent of the indemnified party unless such settlement, compromise or consent secures the unconditional release of the indemnified party from all liabilities arising out of such Claim; provided, further, that if
the defendants in any such Claim include both the indemnified party and the indemnifying party and the indemnified party reasonably determines, based upon advice of legal counsel experienced in such matters, that such Claim involves a conflict of
interest (other than one of a monetary nature) that would reasonably be expected to make it inappropriate for the same counsel to represent both the indemnifying party and the indemnified, then the indemnifying party shall not be entitled to assume
the defense of the indemnified party and the indemnified party shall be entitled to separate counsel at the indemnifying party’s expense, which counsel shall be chosen by the indemnified party and approved by the indemnifying party, which
approval shall not be unreasonably withheld; and provided, further, that it is understood that the indemnifying party shall not be liable for the fees, charges and disbursements of more than one separate firm for the indemnified party.
All reasonable fees and third party expenses subject to indemnification hereunder (including any reasonable fees and expenses incurred in connection with investigating or preparing to defend such action or proceeding) will be paid to the indemnified
party (provided appropriate documentation for such expenses is also submitted with such notice), as incurred, within five calendar days of written notice thereof to the indemnifying party (regardless of whether it is ultimately determined that an
indemnified party is not entitled to indemnification hereunder; provided, however that the indemnified party will be required to repay to the indemnifying party any amounts paid to it for which it is determined the indemnified party was not
otherwise entitled within five calendar days of such determination). 
 (c) If the indemnifying party assumes the defense of any Claim, all
indemnified parties shall thereafter deliver to the indemnifying party copies of all notices and documents (including court papers) received by the indemnified party relating to the Claim, and each indemnified party shall cooperate in the defense or
prosecution of such Claim. Such cooperation shall include the retention and (upon the indemnifying party’s request) the provision to the indemnifying party of records and information that are reasonably relevant to such Claim, and making
employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. If the indemnifying party is not entitled to assume the defense of such Claim as a result of the second proviso
to the second sentence of Section 7.9(b), the indemnifying party’s counsel shall be entitled to conduct the indemnifying party’s defense and counsel for the indemnified party shall be entitled to conduct the defense of the indemnified
party, it being understood that both such counsel will cooperate with each other, to the extent feasible in light of the conflict of interest or different available legal defenses, to conduct the defense of such action or proceeding as efficiently
as possible. If the indemnifying party is not so entitled to assume the defense of such action or does not assume the defense, after having received the notice referred to in the first sentence of Section 7.9(a), the indemnifying party will pay
the reasonable fees and expenses of counsel for the indemnified party; in that event, however, the indemnifying party will not be liable for any settlement of any Claim effected without the written consent of the indemnifying party. If an
indemnifying party is entitled to assume, and assumes, the defense of an action or proceeding in accordance with Section 7.9(b), the indemnifying party shall not be liable for any fees and expenses of counsel for 

  

 42 







 
the indemnified party incurred thereafter in connection with that action or proceeding except as set forth in the second proviso in the second sentence of
Section 7.9(b). Unless and until a final judgment is rendered that an indemnified party is not entitled to the costs of defense under the provisions of this Section 7.9, the indemnifying party shall reimburse, promptly as they are
incurred, the indemnified party’s costs of defense. 
 7.10 Contribution. 
 (a) If the indemnification provided for in Section 7.7 or 7.8 hereof is applicable in accordance with its terms, but if determined by a court of
competent jurisdiction to be legally unenforceable in respect of any losses, claims, damages, actions, liabilities, costs or expenses referred to therein, then each indemnifying party, in lieu of indemnifying such indemnified party, shall contribute
to the amount paid or payable by indemnified party as a result of such losses, claims, damages, actions, liabilities, costs or expenses as between the Company on the one hand and Purchasers on the other, in such proportion as is appropriate to
reflect the relative fault of the Company on the one hand and of Purchasers on the other in connection with such statements or omissions which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative fault of the Company on the one hand and of Purchasers on the other shall be determined by reference to, among other things, whether the action in question, including any untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, the Company or Purchasers, and the Company’s and each Purchaser’s relative intent, knowledge, access to information
and opportunity to correct or prevent such action. 
 (b) The Company and Purchasers agree that it would not be just and equitable if
contribution pursuant to this Section 7.10 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in Section 7.10(a). The amount
paid or payable by an indemnifying party as a result of the losses, claims, damages or liabilities referred to in Sections 7.7 and 7.8 hereof shall be deemed to include, subject to the limitations set forth above, any legal or other expenses
reasonably incurred by the indemnified party in connection with investigating or defending any such action or claim. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 7.10, each person, if any, who controls a Purchaser within the meaning of Section 15 of the Securities Act shall have the
same rights to contribution as such Purchaser, and each director of the Company and each officer of the Company who signed a Registration Statement shall have the same rights to contribution as the Company. 
 7.11 Rule 144 Reporting. With a view to making available to Purchasers the benefits of certain rules and regulations of the SEC which may
permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to: 
 (a) make and keep public information available, as those terms are understood and defined in Rule 144(c)(1) under the Securities Act or any similar or analogous rule promulgated under the Securities Act, at all times after the effective
date of this Agreement; 
  

 43 







 (b) file with the SEC, in a timely manner, all reports and other documents required of the Company under
the Exchange Act; and 
 (c) furnish to each Purchaser forthwith upon request: a written statement by the Company as to its compliance with
the reporting requirements of Rule 144 under the Securities Act, and of the Exchange Act; a copy of the most recent annual or quarterly report of the Company; and such other reports and documents as such Purchaser may reasonably request in availing
itself of any rule or regulation of the SEC allowing it to sell any such securities without registration. 
 ARTICLE 8 
 Conditions 
 8.1
Conditions to Each Party’s Obligations to Close the Transaction. The obligation of each Purchaser to purchase its portion of the Shares, and of the Company to issue and sell the Shares, at Closing is subject to the fulfillment of
the following conditions as of the Closing Date: 
 (a) No Injunction. No Governmental Authority of competent jurisdiction shall have
enacted, issued, promulgated, enforced or entered any statute, law, ordinance, rule, regulation, judgment, decree, injunction or other order (whether temporary, preliminary or permanent) that is in effect and restrains, enjoins or otherwise
prohibits consummation of any transaction contemplated by this Agreement (collectively, an “Order”). 
 8.2 Conditions
to the Obligations of Purchasers. The obligation of each Purchaser to purchase its portion of the Shares is, at the option of such Purchaser, subject to the fulfillment of the following conditions as of the Closing Date: 
 (a) Representations and Warranties. (i) The representations and warranties in Section 3.7(a)(ii) shall be true and correct in all
respects on and as of the date of this Agreement and on and as of the Closing Date, and (ii) the other representations and warranties of the Company set forth in this Agreement (without regard to any “material,” “Material Adverse
Effect” or other materiality qualifier) shall be true and correct in all respects on and as of the date of this Agreement and on and as of the Closing Date (except to the extent such representations and warranties relate to an earlier date, in
which case such representations and warranties shall be true and correct on and as of such earlier date); provided, however, that in the event of a breach of a representation or warranty of the type described in Section 8.2(a)(ii), the
condition set forth in this Section 8.2(a) shall be deemed satisfied unless the effect of all such breaches of representations and warranties taken together would reasonably be likely to have a Material Adverse Effect. 
  

 44 







 (b) Covenants. The Company shall have performed or complied in all material respects with all
covenants of the Company in this Agreement. 
 (c) Bringdown Certificate. The Company shall have delivered to Purchasers a certificate
of the Company, executed by an executive officer of the Company, dated the Closing Date, and certifying to the fulfillment of the conditions specified in clauses (a) and (b) of this Section 8.2. 
 (d) Regulatory Approvals. All approvals of Governmental Authorities required in connection with the execution, delivery and performance of this
Agreement and the consummation of the Transaction by Purchasers, including any necessary approvals of the FRB, the FDIC, the ASBD and the Office of Thrift Supervision (the “OTS”), shall have been made or obtained (as the case may
be) and shall remain in full force and effect and all statutory waiting periods in respect thereof shall have expired, and none of the approvals shall contain any conditions, restrictions or requirements which would reasonably be likely
(i) following the Closing Date, to, individually or in the aggregate, have a material adverse effect on a Purchaser or any of its Affiliates or (ii) to be materially and unreasonably burdensome on a Purchaser or any of its Affiliates.

 (e) NYSE Notice Period. The ten (10) day notice period set forth in Paragraph 312.05 of the NYSE Listed Company Manual shall
have passed after the notice to the stockholders required thereunder and under Section 6.4(a) has been provided or the Company has otherwise complied with Section 6.4(a). 
 (f) TARP Capital Purchase Program. Purchasers shall have received satisfactory confirmation that the United States Treasury, immediately after the
Company’s receipt of the Purchase Price (directly or through an escrow account to be released at Closing), will invest funds in the Company through the TARP Capital Purchase Program in an amount equal to three percent (3%) of the
risk-weighted assets of the Company as determined by Treasury’s normal calculations. 
 (g) Conversion. Colonial Bank shall have
converted to a federal savings and loan association, and the Transaction shall not have been subject to Regulation Y under the Bank Holding Company Act, as amended. 
 (h) Regulation W Issues. Purchasers shall have received such approvals, clearances and/or waivers from the OTS, to the reasonable satisfaction of the Required Purchasers, as to the applicability of Regulation
W. 
 (i) Reserved. 
 (j)
No Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any circumstance, change in or effect on the Company that, individually or in the aggregate, has had or is reasonably likely to result in a Material
Adverse Effect. 
  

 45 







 (k) Financing. Purchasers shall have obtained financing in such amounts and on such terms as
Purchasers in their sole discretion deem reasonable and necessary to consummate the Transaction. 
 (l) Due Diligence Review.
Purchasers and their representatives shall have completed the due diligence review of the operations, condition (financial and other), prospects, assets and liabilities of, and other matters related to, the Company to the satisfaction of Purchasers
in their sole discretion; provided, however, that from and after May 1, 2009, this condition shall be deemed to be satisfied. 
 (m) No Proceedings. Since the date of this Agreement, there shall have been no litigation, claim, action, suit or other proceeding (other than proceedings relating to the matters described in subparagraphs (d), (g) and
(h) above) (i) involving any challenge to, or seeking damages or other relief in connection with, the Transaction or (ii) that could reasonably be expected to have the effect of preventing, delaying or otherwise materially interfering
with the Transaction. 
 (n) Accounting for Investment. Purchasers shall be satisfied that (i) the sale of the Shares by the
Company will not trigger a “change of control” for accounting purposes and will not be required to mark its balance sheet to current market prices and (ii) the investment by each Purchaser will be recorded as an “equity
investment” and/or a “minority investment” on such Purchaser’s books and will not be required to follow consolidation method of accounting on such Purchaser’s books. 
 8.3 Conditions to Closing of Company. The Company’s obligation to sell and issue the Shares is, at the option of the Company, subject
to the fulfillment of the following conditions as of the Closing Date: 
 (a) Representations and Warranties. The representations and
warranties of each Purchaser in this Agreement (without regard to any “material” or “material adverse effect” qualifiers) shall be true and correct on and as of the date of this Agreement and on and as of the Closing (except to
the extent such representations and warranties relate to an earlier date, in which case such representations and warranties shall be true and correct on and as of such earlier date); provided, however, that in the event of a breach of a
representation or warranty of a Purchaser, the condition set forth in this Section 8.3(a) shall be deemed satisfied unless the effect of all such breaches of representations and warranties by all Purchasers taken together would reasonably be
likely to prevent or materially impede or delay the consummation of the transactions contemplated by this Agreement. 
 (b) Covenants.
Each Purchaser shall have performed or complied in all material respects with all covenants of such Purchaser in this Agreement. 
 (c)
Bringdown Certificate. Each Purchaser shall have delivered to the Company a certificate of such Purchaser, executed by an executive officer of such Purchaser, dated the Closing Date, and certifying to the fulfillment of the conditions
specified in clauses (a) and (b) of this Section 8.3. 
  

 46 







 (d) Regulatory Approvals. All approvals of Governmental Authorities required in connection with
the execution, delivery and performance of this Agreement and the consummation of the Transaction by Purchasers, including any necessary approvals of the FRB, the FDIC, the ASBD and the OTS, shall have been made or obtained (as the case may be) and
shall remain in full force and effect and all statutory waiting periods in respect thereof shall have expired, and none of the approvals shall contain any conditions, restrictions or requirements which would reasonably be likely (i) following
the Closing Date, to, individually or in the aggregate, have a Material Adverse Effect on the Company, (ii) be materially and unreasonably burdensome on the Company or any of its Subsidiaries or Affiliates or (iii) to require the sale by
the Company or any Company Subsidiary or Affiliates of any assets. 
 (e) Accounting for Investment. The Company shall be satisfied
that (i) the sale of the Shares by the Company will not trigger a “change of control” for accounting purposes and will not be required to mark its balance sheet to current market prices and (ii) the investment by each Purchaser
will be recorded as an “equity investment” and/or a “minority investment” on such Purchaser’s books and will not be required to follow consolidation method of accounting on such Purchaser’s books. 
 (f) TARP Capital Purchase Program. The Company shall have received satisfactory confirmation that the United States Treasury, immediately after
the Company’s receipt of the Purchase Price (directly or through an escrow account to be released at Closing), will invest funds in the Company through the TARP Capital Purchase Program in an amount equal to three percent (3%) of the
risk-weighted assets of the Company as determined by Treasury’s normal calculations. 
 (g) Joinder by Purchasers. This Agreement
shall have been executed by the Purchasers listed on Schedule 1 no later than April 30, 2009. 
 ARTICLE 9 
 Termination and Amendment 
 9.1
Termination. Notwithstanding any other provision of this Agreement, this Agreement may be terminated at any time prior to the Closing: 
 (a) by either the Required Purchasers or the Company if the Closing shall not have occurred by July 31, 2009 (the “Termination Date”), provided, however that the right to terminate this Agreement under this
Section 9.1(a) shall not be available to any party whose breach of any representation or warranty or failure to perform any obligation under this Agreement shall have caused or resulted in the failure of the Closing to occur on or prior to such
date; or 
 (b) by either the Required Purchasers or the Company in the event that any Governmental Authority shall have issued an Order and
such Order shall have become final and nonappealable; or 
  

 47 







 (c) by the Company if there has been a material breach of any representation, warranty, covenant or
agreement made by a Purchaser in this Agreement, or any such representation and warranty shall have become untrue after the date of this Agreement, such that Section 8.3(a) or (b) (as the case may be) would not be satisfied and such breach
or condition is not curable or, if curable, is not cured within the earlier of (i) thirty (30) days after written notice thereof is given by the Company to Purchasers and (ii) the Termination Date; or 
 (d) by the Required Purchasers if there has been a material breach of any representation, warranty, covenant or agreement made by the Company in this
Agreement, or any such representation and warranty shall have become untrue after the date of this Agreement, such that Section 8.2(a) or (b) (as the case may be) would not be satisfied and such breach or condition is not curable or, if
curable, is not cured within the earlier of (i) thirty (30) days after written notice thereof is given by the Required Purchasers to the Company and (ii) the Termination Date; or 
 (e) by the Required Purchasers, if the Company enters into any agreement with respect to an Acquisition Proposal other than the Transaction, or if the
Company Board recommends to its stockholders an Acquisition Proposal other than the Transaction (or, in the event of a tender offer for Company Common Stock, fails to recommend the Transaction to its stockholders); or 
 (f) by the Company, if the Company enters into any agreement with respect to a Superior Proposal following the Company’s compliance with
Section 6.5; or 
 (g) by the Required Purchasers, if the condition set forth in Section 8.2(l) shall not have been satisfied by
April 30, 2009; or 
 (h) by (i) either the Required Purchasers or the Company if the closing conditions set forth in
Section 8.1 shall not have been satisfied, (ii) the Required Purchasers if the closing conditions set forth in Section 8.2 (other than Section 8.2(l)) shall not have been satisfied, or (iii) the Company if the closing
conditions set forth in Section 8.3 shall not have been satisfied, in each case with respect to the foregoing (i), (ii) or (iii) by July 31, 2009; or 
 (i) by the Company if the joinder to this Agreement has not been executed by April 30, 2009; 
 (j) by
the mutual written consent of the Required Purchasers and the Company. 
 Except in the case of a mutual termination pursuant to
Section 9.1(j), the party desiring to terminate this Agreement pursuant to this Section 9.1 shall give written notice of such termination to the other party in accordance with Section 10.6, specifying the provision or provisions
hereof pursuant to which such termination is effected. 
 9.2 Effect of Termination. In the event of termination of this
Agreement as provided in this Section 9.1, this Agreement shall forthwith become void, except that (i) nothing herein shall relieve any party from liability for any breach of this Agreement, material 

  

 48 







 
misrepresentation or fraud and (ii) Sections 6.10 and 9.2 and Article 10 shall survive any termination of this Agreement; and provided further
that in the case of a termination of this Agreement pursuant to Section 9.1(d), 9.1(e) or 9.1(f) (or any other provision as it relates to the matters in Section 9.1(d), 9.1(e) or 9.1(f)), the Company shall pay to TBW, upon written demand,
an aggregate amount in cash equal to Ten Million Dollars ($10,000,000.00), which amount would constitute liquidated damages and such Purchaser’s receipt thereof would be Purchasers’ sole and exclusive remedy under this Agreement for any
and all breaches of this Agreement by the Company. In the event of payment of the termination fee above, there will be no further indemnification obligations hereunder. 
 9.3 Amendment. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the party
against whom enforcement of any such amendment, waiver, discharge or termination is sought. 
 ARTICLE 10 
 Miscellaneous 
 10.1
Governing Law; Venue. This Agreement shall be deemed to be made in and in all respects shall be interpreted, construed and governed by and in accordance with the laws of the State of Delaware. The parties hereby irrevocably submit to
the jurisdiction of the courts of the State of Delaware and the federal courts of the United States of America located in the State of Florida solely for the purposes of any suit, action or other proceeding between any of the parties hereto arising
out of this Agreement or any transaction contemplated hereby, and hereby waive, and agree to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof, that it is not subject thereto or that such action,
suit or proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement may not be enforced in or by such courts, and the parties hereto irrevocably agree that all claims
with respect to such action or proceeding shall be heard and determined in such Delaware state or Florida federal court. The parties hereby consent to and grant any such court jurisdiction over the person of such parties and over the subject matter
of such dispute and agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in Section 10.6 or in such other manner as may be permitted by law, shall be valid and sufficient service
thereof. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 10.2 Attorney’s Fees. In the event of any action of any kind between the parties hereto with respect to this Agreement, the prevailing
party shall be entitled to recover from the other party its attorney’s fees and related costs and expenses incurred in connection with such action. 
 10.3 Survival. The representations and warranties made herein shall survive the Closing Date and shall expire on the date that is six (6) months following the Closing Date. The covenants contained
herein shall survive in accordance with their respective terms. 
  

 49 







 10.4 Successors and Assigns. Except as otherwise provided herein, the provisions hereof
shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 
 10.5 Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof, and no party shall be liable or bound to any other party in
any manner by any warranties, representations or covenants except as specifically set forth herein or therein. 
 10.6 Notices,
Etc. Any notice, request, instruction or other document to be given hereunder by any party to the other will be in writing and will be deemed to have been duly given (i) on the date of delivery if delivered personally or by telecopy or
facsimile, upon confirmation of receipt, (ii) on the first Business Day following the date of dispatch if delivered by a recognized next-day courier service, or (iii) on the third Business Day following the date of mailing if delivered by
registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered as set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice.

 If to Purchasers to them at the respective addresses set forth on the signature page hereto. 
 with a copy to (which copy alone shall not constitute notice): 
 Locke Lord Bissell & Liddell LLP 
 401 9th Street N.W. 
 Suite 400 South 
 Washington, DC 20004

 Attn: Douglas P. Faucette, Esq. 
 Telephone: (202) 220-6961 
 Fax: (202) 220-6945 
 If to the Company to it at: 
 The Colonial
BancGroup, Inc. 
 100 Colonial Bank Boulevard 
 Montgomery, AL 36117 
 Attn: David B. Byrne, Jr., Esq. 
 Telephone: (334) 676-5460 
 Fax:
(334) 676-5069 
  

 50 







 with a copy to (which copy alone shall not constitute notice): 
 Balch & Bingham LLP 
 1901 Sixth
Avenue North, Suite 1500 
 Birmingham, AL 35203 
 Attn: Michael D. Waters, Esq. 
 Telephone: (205) 226-8720 
 Fax: (205) 226-8799 
 10.7
Specific Performance. The Company and Purchasers acknowledge and agree that irreparable damage to the other party would occur in the event that any of the provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached. It is accordingly agreed that each party shall be entitled to an injunction, injunctions or other equitable relief, without the necessity of posting a bond, to prevent or cure breaches of the provisions of
this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which the parties may be entitled by law or equity. 
 10.8 No Third Party Beneficiaries. Other than as set forth in Sections 7.5, 7.6 and 7.8, nothing in this Agreement, expressed or implied,
is intended to confer upon any person, other than the parties hereto or their respective successors, any rights, remedies, obligations or liabilities under or by reason of this Agreement. 
 10.9 Several Obligations. The Company acknowledges and agrees that the obligations of Purchasers under this Agreement are several and not
joint, and that no Purchaser is responsible for any breach of this Agreement by any other Purchaser. Each Purchaser agrees that no Purchaser nor the respective officers, directors, partners, agents, or employees of any Purchaser shall be liable to
any other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the purchase of the Shares or the Transaction. 
 10.10 No Assignment. This Agreement shall not be assignable by operation of law or otherwise; provided, however, that any Purchaser may assign all or part of its rights and obligations
under this Agreement without the Company’s consent to any Affiliate, but only if the assignee agrees in writing with the Company in form and substance reasonably satisfactory to the Company to be bound by the terms of this Agreement and in
conjunction therewith, makes to the Company representations and warranties substantially equivalent (with necessary conforming changes) to those contained in Article 4 as if such assignee were a “Purchaser” therein (any such transferee
shall be included in the term “Purchaser”); provided, further, that no such assignment shall be permitted without the Company’s consent if it (i) would reasonably be expected to adversely affect or delay the receipt
of the approvals of any Governmental Authority described in Section 6.3, (ii) would require any consents or approvals from or filings or notices with any Governmental Authority or other person not identified in Section 6.3 or
(iii) would reasonably be expected to adversely affect or delay the consummation of the transactions contemplated hereby. 
 10.11
Expenses. The Company and Purchasers shall bear their own respective expenses incurred on its behalf with respect to this Agreement and the Transaction, except with respect to Purchasers’ reasonable costs and expenses associated
with due diligence and documentation 

  

 51 







 
relating to the Transaction, which shall be borne by the Company up to $1,000,000 as set forth in that certain Reimbursement Agreement between the Company
and TBW dated on or about March 18, 2009, and with respect to fees described in Section 3.17 which shall be borne by the Company. 
 10.12 Counterparts; Effectiveness. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall
constitute one instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or by PDF formatted page sent by electronic mail shall be effective as delivery of a manually executed counterpart of this Agreement.
This Agreement shall become effective upon the execution of this Agreement by all of the parties listed on the signature pages hereto. 
 10.13 Severability. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect
without said provision; provided that no such severability shall be effective if it materially changes the economic benefit of this Agreement to any party. 
 10.14 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not considered in construing or interpreting this Agreement. 
 [SIGNATURES BEGIN ON FOLLOWING PAGE] 
  

 52 







 IN WITNESS WHEREOF, the Company and Purchasers have caused this Stock Purchase Agreement to
be duly executed and delivered as of the date first above written. 
  

							
	“COMPANY”:	 		 	 THE COLONIAL BANCGROUP, INC.,
 a
Delaware corporation

				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  









							
	“PURCHASERS”:	 		 		 	
			
	 Address for Notices:
 315 NE 14th
Street
 Ocala, FL 34470
 Attn: Lee B. Farkas, Chairman

Telephone: (352) 351-1109
 Fax: (352) 867-1190
	 		 	 TAYLOR, BEAN & WHITAKER MORTGAGE CORP.,
 a Florida corporation
  

	 		 	By:	 	  

	 		 	Name:	 	  

	 		 	Title:	 	  








 Exhibit A 
 Form of Certificate of Designations 






 CERTIFICATE OF DESIGNATIONS OF 
 SERIES A VOTING CONVERTIBLE PREFERRED STOCK 
 AND 
 SERIES B NONVOTING CONVERTIBLE PREFERRED STOCK 
 OF 
 THE COLONIAL BANCGROUP, INC. 
 Pursuant to Section 151 of the 
 General Corporation Law of the State of Delaware 
  
  
 THE COLONIAL BANCGROUP, INC., a Delaware corporation (the “Corporation”), certifies as follows: 
 FIRST: The Amended and Restated Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”) authorizes the
issuance of One Million (1,000,000) shares of Preference Stock, par value $2.50 per share, and, further, authorizes the Board of Directors of the Corporation, subject to the limitations prescribed by law and the provisions of such Certificate
of Incorporation, to provide for the issuance of shares of the Preference Stock or to provide for the issuance of shares of the Preference Stock in one or more series, to establish from time to time the number of shares to be included in each such
series and to fix the designations, voting powers, preference rights and qualifications, limitations or restrictions of the shares of the Preference Stock of each such series. 
 SECOND: The Board of Directors of the Corporation, at a special meeting duly called on and held on March
        , 2009, duly adopted the following resolutions, authorizing the creation and issuance of two series of Preference Stock, to be known, respectively, as Series A Voting Convertible Preferred Stock and
Series B Nonvoting Convertible Preferred Stock: 
 RESOLVED, that the Board of Directors, pursuant to the authority vested in it by the
provisions of the Certificate of Incorporation of the Corporation, hereby authorizes the issuance of two series of the Corporation’s Preference Stock, par value $2.50 per share, Four Hundred Sixty Six Thousand Six Hundred (466,600) shares
of which are authorized to be issued under the Corporation’s Certificate of Incorporation and being designated as Series A Voting Convertible Preferred Stock (hereinafter referred to as the “Series A Preferred Stock”), and One Hundred
Thirty Three Thousand Four Hundred (133,400) shares of which are authorized to be issued under the Corporation’s Certificate of Incorporation and being designated as Series B Nonvoting Convertible Preferred Stock (hereinafter referred to
as the “Series B Preferred Stock”); and further 
 RESOLVED, that the Board of Directors hereby fixes the number, designations,
preferences, rights and limitations of the Series A Preferred Stock and the Series B Preferred Stock, in addition to those set forth in said Certificate of Incorporation as follows: 
  

 62 








	 	A.	Series A Voting Convertible Preferred Stock. 

 1. Designation and Amount. 
 There shall be a series of Preferred Stock designated as Series A Voting Convertible Preferred
Stock (“Series A Preferred Stock”) and the number of shares constituting such series shall be Four Hundred Sixty Six Thousand Six Hundred (466,600). Such number of shares may be increased or decreased by resolution of the Board of
Directors, provided that no decrease shall reduce the number of Series A Preferred Stock to a number less than the number of shares then outstanding or reserved for issuance in certain events. 
 2. Dividends. 
 The holders of the
outstanding Series A Preferred Stock shall be entitled to receive dividends or distributions on an as-converted and pari passu basis with the Corporation’s now or hereafter issued Series B Preferred Stock and Common Stock, and each other
series of capital stock of the Corporation that is not, by its terms, senior to the Series A Preferred Stock, if, as and when declared by the Board of Directors or any duly authorized committee thereof, but only out of assets legally available
therefore. 
 3. Liquidation Rights. 
 All shares of Series A Preferred Stock shall rank pari passu, on an as-converted basis, as to distributions of assets upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation,
to all of the Corporation’s now or hereafter issued Common Stock, Series B Preferred Stock, and any other series of capital stock of the Corporation that is not, by its terms, senior to the Series A Preferred Stock. 
 4. Voting Rights. 
 The holders of
Series A Preferred Stock shall have the right to vote, on an as-converted basis, with the Common Stock on all matters as and to the extent permitted by the Delaware General Corporation Law. In connection with any such vote, each outstanding share of
Series A Preferred Stock shall be entitled to a number of votes equal to the number of shares of Common Stock into which such share of Series A Preferred Stock is then convertible pursuant to Section 6 hereof as of the record date for the vote
or written consent of stockholders, if applicable, which is initially one thousand (1,000) votes per share. So long as any Series A Preferred Stock is outstanding, the Corporation shall not, without the affirmative vote of the holders of at
least 66 2/3 percent of all outstanding shares of Series A Preferred Stock, voting separately as a class, whether or not a vote of the stockholders would otherwise be required by law, (i) amend, alter or repeal (by merger or otherwise) any
provision of the Certificate of Incorporation or the Bylaws of the Corporation so as to affect adversely the relative rights, preferences, qualifications, limitations or restrictions of the Series A Preferred Stock (other than to create or establish
any capital stock issued or to be issued to the United States Treasury as part of the TARP Capital Purchase Program or any similar governmental program), (ii) authorize or issue, or increase the authorized amount of, any additional class or
series of stock of the Corporation, or any security convertible into stock of such class or series, having rights senior to or pari passu with the Series A Preferred Stock as to dividends or liquidation (other than any capital stock issued to
the United States Treasury as part of the TARP Capital Purchase Program or any similar governmental 

  

 63 







 
program) and any right to vote, whether as a separate class or otherwise, on any matter (other than a matter that can have no effect on the rights of the
Series A Preferred Stock) as to which the Series A Preferred Stock is not entitled to vote, (iii) effect any reclassification of the Series A Preferred Stock, or (iv) enter into a merger or consolidation with, or sell or transfer all
or substantially all of its assets to, another person or entity. 
 5. Redemption. 
 The Corporation has no optional or mandatory redemption, retirement or sinking fund obligation with respect to the Series A Preferred Stock. 

6. Conversion. 
 (a) Date of
Conversion. Each share of Series A Preferred Stock shall be convertible, at the option of the holder thereof, into Common Stock as provided in and pursuant to Section 6(b) below, no later than the later of (A) the date of the
Corporation’s receipt of Stockholder Approval or the date that is three months after the date of issuance of such share or (B) the date that is three months after the date of issuance of such share provided that Stockholder Approval has
been received; provided, however, that in no event will such conversion take place if there are an insufficient number of authorized shares of Company Common Stock to effectuate such conversion. “Stockholder Approval” means the
approval of the Corporation’s stockholders of an amendment to the Certificate of Incorporation (i) increasing the number of authorized shares of Common Stock so that there will be a sufficient number of authorized shares of Common Stock to
satisfy the conversion rights of all holders of the shares of Series A Preferred Stock and any other holders of the Corporation’s Preferred Stock or Preference Stock having conversion rights, (ii) reducing the par value of Common Stock to
$0.01 per share, and (iii) authorizing any amendments required by the TARP Capital Purchase Program or any similar governmental program. 
 (b) Effect of Conversion. Upon the occurrence of a conversion as provided in Section 6(a) above, the holder of shares of converted Series A Preferred Stock shall be entitled to receive 1,000 shares of Common Stock of the
Corporation for each share of such converted Series A Preferred Stock, subject to adjustment as provided in Section 6(d) below. From and after any conversion of Series A Preferred Stock, all rights of the holders of converted Series A
Preferred Stock shall cease, except the right to receive Common Stock as provided in this Section 6(b). 
 (c) Conversion
Procedures. Any holder of shares of Series A Preferred Stock desiring to convert such shares shall surrender the certificate or certificates for such shares of Series A Preferred Stock at the Corporation’s principal office, which
certificate or certificates, if the Corporation shall so require, shall be duly endorsed to the Corporation or in blank, or accompanied by proper instruments of transfer to the Corporation or in blank, accompanied by irrevocable written notice to
the Corporation that the holder elects so to convert such shares of Series A Preferred Stock and specifying the name or names (with address) in which a certificate or certificates for Common Stock are to be issued. Following such conversion of the
shares of Series A Preferred Stock described above, certificates that, until such conversion, represented Series A Preferred Stock (“Former Series A Certificates”) shall thereafter represent solely the right to receive the
securities and/or other property to which the holders of such certificates became entitled upon such conversion. However, such holders shall not be entitled to certificates 

  

 64 







 
representing any such securities or to receive any such other property except upon surrender of such Former Series A Certificates at the Corporation’s
principal office. 
 The Corporation will, as soon as practicable after receipt of certificates for Series A Preferred Stock accompanied by
any required written notice and compliance with any other conditions herein contained, deliver to the person for whose account such shares of Series A Preferred Stock were so surrendered, or to such person’s nominee or nominees, certificates
for the number of full shares of Common Stock to which such person shall be entitled as aforesaid. Subject to the following provisions of this paragraph, such conversion shall be deemed to have been made as of the date of such surrender of the
shares of Series A Preferred Stock to be converted, and the person or persons entitled to receive the Common Stock deliverable upon conversion of such Series A Preferred Stock shall be treated for all purposes as the record holder or holders of such
Common Stock on such date; provided, however, that the Corporation shall not be required to convert any shares of Series A Preferred Stock while the stock transfer books of the Corporation are closed for any purpose, but the surrender of Series A
Preferred Stock for conversion during any period while such books are so closed shall become effective for conversion immediately upon the reopening of such books as if the surrender had been made on the date of such reopening, and the conversion
shall be at the conversion rate in effect on such date. 
 (d) Adjustment. The definition of the term “Common Stock”
for purposes of this Section 6 shall be subject to adjustment from time to time in case the Corporation shall (i) pay a dividend or make a distribution on its Common Stock that is paid or made (A) in other shares of stock of
the Corporation or (B) in rights to purchase stock or other securities (other than an event described in this Section 6(d)), (ii) subdivide its outstanding shares of Common Stock into a greater number of shares or
(iii) combine its outstanding shares of Common Stock into a smaller number of shares, then in each such case the definition of “Common Stock” shall be changed so that the holder of any shares of Series A Preferred Stock thereafter
surrendered for conversion shall be entitled to receive the number of shares of Common Stock of the Corporation and other shares and rights to purchase stock or other securities which such holder would have owned or have been entitled to receive
after the happening of any of the events described above had such shares of Series A Preferred Stock been converted immediately prior to the happening of such event. An adjustment made pursuant to this Section 6(d) shall become effective
immediately after the record date in the case of a dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination. In the event that at any time, as a result of any adjustment
made pursuant to this Section 6, the holder of any shares of Series A Preferred Stock thereafter surrendered by conversion shall become entitled to receive any shares of the Corporation other than shares of Common Stock or to receive any
other securities, the number of such other shares or securities so receivable upon conversion of any share of Series A Preferred Stock shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to
the provisions contained in this Section 6 with respect to the Common Stock. 
 (e) No Fractional Shares. No fractional
shares or scrip representing fractional shares of Common Stock shall be issued upon conversion of Series A Preferred Stock. If more than one certificate representing shares of Series A Preferred Stock shall be surrendered for conversion at one time
by the same holder, the number of full shares issuable upon conversion thereof shall be computed on the basis of the aggregate number of shares of Series A Preferred Stock so 

  

 65 







 
surrendered. Instead of any fractional share of Common Stock that would otherwise be issuable upon conversion of any shares of Series A Preferred Stock, the
Corporation will pay a cash adjustment in respect of such fractional interest in an amount equal to the same fraction of the fair market value per share of Common Stock as determined by the Board of Directors or in any manner prescribed by the Board
of Directors. 
 (f) Reclassification, Consolidation, Merger or Sale of Assets. In case of any reclassification of the Common Stock,
any consolidation of the Corporation with, or merger of the Corporation into, any other person, any merger of another person into the Corporation (other than a merger that does not result in any reclassification, conversion, exchange or cancellation
of outstanding shares of Common Stock), any sale or transfer of all or substantially all of the assets of the Corporation or any compulsory share exchange, pursuant to which share exchange the Common Stock is converted into other securities, cash or
other property (any of the foregoing being herein referred to as a “Transaction”), then lawful provision shall be made as part of the terms of such Transaction whereby the holder of each share of Series A Preferred Stock then
outstanding shall have the right to convert such share only into the kind and amount of securities, cash and other property receivable upon such Transaction by a holder of the number of shares of Common Stock of the Corporation into which such share
of Series A Preferred Stock could have been converted immediately prior to such Transaction. As a condition to the consummation of any Transaction, the Corporation shall require that the person formed by such consolidation or resulting from such
merger or that acquires such assets or that acquires the Corporation’s shares, as the case may be, shall make provisions in its certificate or articles of incorporation or other constituent documents to establish such right. Such certificate or
articles of incorporation or other constituent documents shall provide for adjustments which, for events subsequent to the effective date of such certificate or articles of incorporation or other constituent documents, shall be as nearly equivalent
as may be practicable to the adjustments provided for in this Section 6. The above provisions shall similarly apply to successive reclassifications, consolidations, mergers, sales, transfers or share exchanges. 
 (g) Reservation of Shares; Transfer Taxes; Etc. Following Stockholder Approval, the Corporation shall at all times reserve and keep available, out
of its authorized and unissued stock, solely for the purpose of effecting the conversion of the Series A Preferred Stock, such number of shares of its Common Stock and other securities free of preemptive rights as shall from time to time be
sufficient to effect the conversion of all shares of Series A Preferred Stock from time to time outstanding which are then convertible. Prior to Stockholder Approval, the Corporation shall reserve and keep available such number of shares of its
Common Stock as it then has available for such reservation for conversion. The Corporation shall from time to time, in accordance with the laws of the State of Delaware, increase the authorized number of shares of Common Stock and other securities
if at any time the number of shares of Common Stock and other securities not outstanding shall not be sufficient to permit the conversion of all the then outstanding shares of Series A Preferred Stock. The rights of the holders of the Series A
Preferred Stock, and the granting of such rights by the Corporation hereunder, shall not be considered invalid solely by reason of the lack of sufficient authorized but unissued shares to honor the exercise of such conversion rights. If any shares
of Common Stock required to be reserved for purposes of conversion of the Series A Preferred Stock hereunder require registration with or approval of any governmental authority under any Federal or State law before such shares may be issued upon
conversion or exercise, the Corporation will in good faith and as expeditiously as possible endeavor to cause such shares to be duly registered or approved, 

  

 66 







 
as the case may be. The Corporation will pay any and all issue or other taxes that may be payable in respect of any issue or delivery of shares of Common
Stock on conversion of the Series A Preferred Stock. The Corporation shall not, however, be required to pay any tax that may be payable in respect of any transfer involved in the issue or delivery of Common Stock (or other securities or assets) in a
name other than that in which the shares of Series A Preferred Stock so converted were registered, and no such issue or delivery shall be made unless and until the person requesting such issue has paid to the Corporation the amount of such tax or
has established, to the satisfaction of the Corporation, that such tax has been paid. 
 The Corporation shall not take any action that would
cause any equity securities issuable upon conversion of Series A Preferred Stock immediately following such action to be other than fully paid and nonassessable. 
 (h) Prior Notice of Certain Events. In case: 
 (i) the Corporation shall authorize the
granting to the holders of Common Stock of rights or warrants to subscribe for or purchase any shares of stock of any class or of any other rights or warrants (other than any rights specified in paragraph (d)(i)(B) of this Section 6);
or 
 (ii) of any reclassification of Common Stock (other than a subdivision or combination of the outstanding Common Stock, or a
change in par value, or from par value to no par value, or from no par value to par value), or of any consolidation or merger to which the Corporation is a party and for which approval of any stockholders of the Corporation shall be required, or of
the sale or transfer of all or substantially all of the assets of the Corporation or of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or other property; or 
 (iii) of the voluntary or involuntary dissolution, liquidation or winding up of the Corporation; 
 then the Corporation shall cause to be mailed to each holder of record of the outstanding Series A Preferred Stock, at such holder’s address as it shall appear upon
the stock transfer books of the Corporation, at least 15 days prior to the applicable record date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such granting of rights or warrants or,
if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such rights or warrants are to be determined, or (y) the date on which such reclassification, consolidation, merger, sale, transfer,
share exchange, dissolution, liquidation or winding up is expected to become effective, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer, share exchange, dissolution, liquidation or winding up (but neither the failure so to mail such notice nor any defect therein or in the mailing thereof, shall
affect the validity of the corporate action required to be specified in such notice). 
 7. Preemptive Rights. 
 (a) If the Corporation offers to sell Covered Securities (as defined below) in a public or private offering of Covered Securities solely for cash
(a “Qualified Offering”), each holder of  

  

 67 







 
shares of Series A Preferred Stock (a “Holder”) shall be afforded the opportunity to acquire from the Corporation, for the same price
and on the same terms as such Covered Securities are offered, in the aggregate up to the amount of Covered Securities required to enable such Holder to maintain its then-current Holder Percentage Interest (as defined below), but solely to the extent
that any such issuance of shares of Covered Securities would not result in the issuance of Covered Securities that would require a vote of the stockholders of the Corporation pursuant to the listing standards of the New York Stock Exchange or other
nationally recognized stock exchange on which shares of Common Stock are listed. As used in this Section 7, (i) “Holder Percentage Interest” means, as of any date, the percentage equal to (A) the aggregate
number of shares of Common Stock beneficially owned (with the term “beneficial ownership” having the meaning ascribed in Section 13(d)(3) and Rule 13d-3 under the Exchange Act of 1934, as amended) or otherwise held by such Holder as
of such date, calculated on an as-converted basis, divided by (B) the total number of outstanding shares of Common Stock as of such date, calculated on an as-converted basis, and (ii) “Covered Securities” means Common
Stock and any securities convertible into or exercisable or exchangeable for Common Stock, other than securities that are (A) issued by the Corporation pursuant to any employment contract, employee or benefit plan, stock purchase plan, stock
ownership plan, stock option or equity compensation plan or other similar plan where stock is being issued or offered to a trust, other entity to or for the benefit of any employees, potential employees, consultants, officers or director of the
Corporation, (B) issued by the Corporation in connection with a business combination or other merger, acquisition or disposition transaction, (C) issued with reference to the Common Stock of a subsidiary of the Corporation (i.e., a
carve-out transaction), (D) issued as a dividend or in connection with a dividend reinvestment or stockholder purchase plan, (E) issued in exchange for currently outstanding securities, or (F) issued to the United States Treasury as
part of the TARP Capital Purchase Program or any similar governmental program. 
 Prior to making any Qualified Offering of Covered
Securities, the Corporation shall give each Holder written notice of its intention (including, in the case of a registered public offering and to the extent possible, a copy of the prospectus included in the registration statement filed in respect
of such), describing, to the extent then known, the anticipated amount of securities, price (or, in the case of a registered public offering, an estimated range of prices) and other material terms upon which the Corporation proposes to offer the
same. Such Holder shall have thirty (30) days from the provision of such notice to notify the Corporation in writing that it intends to exercise such preemptive purchase rights and as to the amount of Covered Securities such Holder desires to
purchase, up to the maximum amount calculated pursuant to Section 7(a) (the “Designated Securities”). Such notice shall constitute a non-binding indication of interest of such Holder to purchase the amount of Designated
Securities so specified (or a proportionately lesser amount if the amount of Covered Securities to be offered in such Qualified Offering is subsequently reduced) at the price (or range of prices) and other terms set forth in the Corporation’s
notice to it. The failure by such Holder to respond during such thirty (30) day period shall constitute a waiver of preemptive rights in respect of such offering. The obligation of the Corporation to provide such notice shall be subject to such
Holder’s written agreement to confidentiality and restrictions on trading terms reasonably acceptable to the Corporation. 
 If a Holder
exercises such Holder’s preemptive purchase rights provided in this Section 7 with respect to a Qualified Offering that is an underwritten public offering or a private offering made to qualified institutional buyers (as such term is
defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) for resale pursuant to Rule 144A under 

  

 68 







 
the Securities Act, the Corporation shall offer such Holder, if such underwritten public offering or Rule 144A offering is consummated, the Designated
Securities (as adjusted downward or, at such Holder’s option, upward to reflect the actual size of such offering when priced) at the same price as the Covered Securities are offered to the initial purchasers in such offering and shall provide
written notice of such price to such Holder as soon as practicable prior to such consummation. Contemporaneously with the execution of any underwriting agreement or purchase agreement entered into between the Corporation and the underwriters or
initial purchasers of such underwritten public offering or Rule 144A offering, such Holder shall, if it continues to wish to exercise its preemptive rights with respect to such offering, enter into an instrument in form and substance reasonably
satisfactory to the Corporation acknowledging such Holder’s binding obligation to purchase the Designated Securities to be acquired by it and containing representations, warranties and agreements of such Holder that are customary in private
placement transactions and, in any event, no less favorable to such Holder than any underwriting or purchase agreement entered into by the Corporation in connection with such offering, and the failure to enter into such an instrument at or prior to
such time shall constitute a waiver of preemptive rights in respect of such offering. Any offers and sales pursuant to this Section 7(c) in the context of a registered public offering shall also be conditioned on reasonably acceptable
representations and warranties of such Holder regarding its status as the type of offeree to whom a private sale can be made concurrently with a registered offering in compliance with applicable securities laws. 
 If a Holder exercises its preemptive rights provided in this Section 7 with respect to a Qualified Offering that is not an underwritten
public offering or Rule 144A offering (a “Private Placement”), the closing of the purchase of the Covered Securities with respect to which such right has been exercised shall be conditioned on the consummation of the Private
Placement giving rise to such preemptive purchase rights and shall take place simultaneously with the closing of the Private Placement or on such other date as the Corporation and such Holder shall agree in writing; provided that the actual
amount of Covered Securities to be sold to such Holder pursuant to its exercise of preemptive rights hereunder shall be reduced if the aggregate amount of Covered Securities sold in the Private Placement is reduced and, at the option of such Holder
(to be exercised by delivery of written notice to the Corporation within five (5) business days of receipt of notice of such increase), shall be increased if such aggregate amount of Covered Securities sold in the Private Placement is
increased. In connection with its purchase of Designated Securities, such Holder shall, if it continues to wish to exercise its preemptive rights with respect to such offering, execute an agreement containing representations, warranties and
agreements of such Holder that are substantially similar in all material respects to the agreements executed by other purchasers in such Private Placement. 
 If, prior to consummation of a Qualified Offering, the terms of the proposed issuance change with the result that the price is less than the minimum price or more than the maximum price set forth in the notice
contemplated by Section 7(b) or the other principal terms are more favorable in any material respect to the prospective purchaser than those set forth in such notice, it shall be necessary for a separate notice to be furnished, and the
terms and provisions of this Section 7 separately complied with. 
 Anything to the contrary in this Section 7
notwithstanding, the preemptive right to purchase Covered Securities granted by this Section 7 as to a Holder shall terminate as of and not be available for any offering that commences at any time after the date on which such Holder


  

 69 







 
offers, sells, pledges, or otherwise transfers any of the shares of Series A Preferred Stock then held by such Holder, including by way of entry into any
swap or other agreement or transaction that hedges or transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of such shares. In addition, the preemptive rights granted hereunder shall only apply to the initial
Holder of the Covered Securities. 
  

	 	B.	Series B Nonvoting Convertible Preferred Stock. 

 1. Designation and Amount. 
 There shall be a series of Preferred Stock designated as Series B Nonvoting Convertible
Preferred Stock (“Series B Preferred Stock”) and the number of shares constituting such series shall be One Hundred Thirty Three Thousand Four Hundred (133,400). Such number of shares may be increased or decreased by resolution of
the Board of Directors, provided that no decrease shall reduce the number of Series B Preferred Stock to a number less than the number of shares then outstanding or reserved for issuance in certain events. 
 2. Dividends. 
 The holders of the
outstanding Series B Preferred Stock shall be entitled to receive dividends or distributions on an as-converted and pari passu basis with the Corporation’s now or hereafter issued Series A Preferred Stock and Common Stock, and each other
series of capital stock of the Corporation that is not, by its terms, senior to the Series B Preferred Stock, if, as and when declared by the Board of Directors or any duly authorized committee thereof, but only out of assets legally available
therefore. 
 3. Liquidation Rights. 
 All shares of Series B Preferred Stock shall rank pari passu, on an as-converted basis, as to distributions of assets upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation,
to all of the Corporation’s now or hereafter issued Common Stock, Series A Preferred Stock, and any other series of capital stock of the Corporation that is not, by its terms, senior to the Series B Preferred Stock. 
 4. Voting Rights. 
 The holders of
Series B Preferred Stock shall not have any voting powers, either general or special, except to the extent required by the Delaware General Corporation Law; provided, however, that so long as any Series B Preferred Stock is outstanding, the
Corporation shall not, without the affirmative vote of the holders of at least 66 2/3 percent of all outstanding shares of Series B Preferred Stock, voting separately as a class, whether or not a vote of the stockholders would otherwise be required
by law, (i) amend, alter or repeal (by merger or otherwise) any provision of the Certificate of Incorporation or the Bylaws of the Corporation so as to affect adversely the relative rights, preferences, qualifications, limitations or
restrictions of the Series B Preferred Stock (other than any capital stock issued to the United States Treasury as part of the TARP Capital Purchase Program or any similar governmental program), (ii) authorize or issue, or increase the
authorized amount of, any additional class or series of stock of the Corporation, or any security convertible into stock of such class or series, having rights senior to or pari passu with the Series B Preferred Stock as to dividends or
liquidation (other than any capital stock 

  

 70 







 
issued to the United States Treasury as part of the TARP Capital Purchase Program or any similar governmental program) and any right to vote, whether as a
separate class or otherwise, on any matter (other than a matter that can have no effect on the rights of the Series B Preferred Stock) as to which the Series B Preferred Stock is not entitled to vote, (iii) effect any reclassification of
the Series B Preferred Stock, or (iv) enter into a merger or consolidation with, or sell or transfer all or substantially all of its assets to, another person or entity. 
 5. Redemption. 
 The Corporation has
no optional or mandatory redemption, retirement or sinking fund obligation with respect to the Series B Preferred Stock. 
 6.
Conversion. 
 (a) Date of Conversion. Each share of Series B Preferred Stock shall be convertible, at the option of the holder
thereof, into Common Stock as provided in and pursuant to Section 7(b) below, no later than the later of (A) the date of the Corporation’s receipt of Stockholder Approval or the date that is three months after the date of
issuance of such share or (B) the date that is three months after the date of issuance of such share provided that Stockholder Approval has been received; provided, however, that in no event will such conversion take place if there are an
insufficient number of authorized shares of Company Common Stock to effectuate such conversion and provided further, that if such share of Series B Preferred Stock is held by the initial holder of such share or any of its affiliates, the ability of
the initial holder or such affiliate to convert such share will be restricted as described in the legend of the stock certificate representing such share. “Stockholder Approval” means the approval of the Corporation’s
stockholders of an amendment to the Certificate of Incorporation (i) increasing the number of authorized shares of Common Stock so that there will be a sufficient number of authorized shares of Common Stock to satisfy the conversion rights of
all holders of the shares of Series B Preferred Stock and any other holders of the Corporation’s Preferred Stock or Preference Stock having conversion rights, (ii) reducing the par value of Common Stock to $0.01 per share, and
(iii) authorizing any amendments required by the TARP Capital Purchase Program or any similar governmental program. 
 (b) Effect of
Conversion. Upon the occurrence of a conversion as provided in Section 6(a) above, the holder of shares of converted Series B Preferred Stock shall be entitled to receive 1,000 shares of Common Stock of the Corporation for each share
of such converted Series B Preferred Stock, subject to adjustment as provided in Section 6(d) below. From and after any conversion of Series B Preferred Stock, all rights of the holders of converted Series B Preferred Stock shall cease,
except the right to receive Common Stock as provided in this Section 6(b). 
 (c) Conversion Procedures. Any holder of shares
of Series B Preferred Stock desiring to convert such shares shall surrender the certificate or certificates for such shares of Series B Preferred Stock at the Corporation’s principal office, which certificate or certificates, if the Corporation
shall so require, shall be duly endorsed to the Corporation or in blank, or accompanied by proper instruments of transfer to the Corporation or in blank, accompanied by irrevocable written notice to the Corporation that the holder elects so to
convert such shares of Series B Preferred Stock and specifying the name or names (with address) in which a certificate or certificates for Common Stock are to be issued. Following such conversion of the shares of 

  

 71 







 
Series B Preferred Stock described above, certificates that, until such conversion, represented Series B Preferred Stock (“Former Series B
Certificates”) shall thereafter represent solely the right to receive the securities and/or other property to which the holders of such certificates became entitled upon such conversion. However, such holders shall not be entitled to
certificates representing any such securities or to receive any such other property except upon surrender of such Former Series B Certificates at the Corporation’s principal office. 
 The Corporation will, as soon as practicable after receipt of certificates for Series B Preferred Stock accompanied by any required written notice and
compliance with any other conditions herein contained, deliver to the person for whose account such shares of Series B Preferred Stock were so surrendered, or to such person’s nominee or nominees, certificates for the number of full shares of
Common Stock to which such person shall be entitled as aforesaid. Subject to the following provisions of this paragraph, such conversion shall be deemed to have been made as of the date of such surrender of the shares of Series B Preferred Stock to
be converted, and the person or persons entitled to receive the Common Stock deliverable upon conversion of such Series B Preferred Stock shall be treated for all purposes as the record holder or holders of such Common Stock on such date; provided,
however, that the Corporation shall not be required to convert any shares of Series B Preferred Stock while the stock transfer books of the Corporation are closed for any purpose, but the surrender of Series B Preferred Stock for conversion during
any period while such books are so closed shall become effective for conversion immediately upon the reopening of such books as if the surrender had been made on the date of such reopening, and the conversion shall be at the conversion rate in
effect on such date. 
 (d) Adjustment. The definition of the term “Common Stock” for purposes of this
Section 6 shall be subject to adjustment from time to time in case the Corporation shall (i) pay a dividend or make a distribution on its Common Stock that is paid or made (A) in other shares of stock of the Corporation or
(B) in rights to purchase stock or other securities (other than an event described in this Section 6(d)), (ii) subdivide its outstanding shares of Common Stock into a greater number of shares or (iii) combine its
outstanding shares of Common Stock into a smaller number of shares, then in each such case the definition of “Common Stock” shall be changed so that the holder of any shares of Series B Preferred Stock thereafter surrendered for conversion
shall be entitled to receive the number of shares of Common Stock of the Corporation and other shares and rights to purchase stock or other securities which such holder would have owned or have been entitled to receive after the happening of any of
the events described above had such shares of Series B Preferred Stock been converted immediately prior to the happening of such event. An adjustment made pursuant to this Section 6(d) shall become effective immediately after the record
date in the case of a dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination. In the event that at any time, as a result of any adjustment made pursuant to this
Section 6, the holder of any shares of Series B Preferred Stock thereafter surrendered by conversion shall become entitled to receive any shares of the Corporation other than shares of Common Stock or to receive any other securities, the
number of such other shares or securities so receivable upon conversion of any share of Series B Preferred Stock shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions
contained in this Section 6 with respect to the Common Stock. 
  

 72 







 (e) No Fractional Shares. No fractional shares or scrip representing fractional shares of Common
Stock shall be issued upon conversion of Series B Preferred Stock. If more than one certificate representing shares of Series B Preferred Stock shall be surrendered for conversion at one time by the same holder, the number of full shares issuable
upon conversion thereof shall be computed on the basis of the aggregate number of shares of Series B Preferred Stock so surrendered. Instead of any fractional share of Common Stock that would otherwise be issuable upon conversion of any shares of
Series B Preferred Stock, the Corporation will pay a cash adjustment in respect of such fractional interest in an amount equal to the same fraction of the fair market value per share of Common Stock as determined by the Board of Directors or in any
manner prescribed by the Board of Directors. 
 (f) Reclassification, Consolidation, Merger or Sale of Assets. In case of any
reclassification of the Common Stock, any consolidation of the Corporation with, or merger of the Corporation into, any other person, any merger of another person into the Corporation (other than a merger that does not result in any
reclassification, conversion, exchange or cancellation of outstanding shares of Common Stock), any sale or transfer of all or substantially all of the assets of the Corporation or any compulsory share exchange, pursuant to which share exchange the
Common Stock is converted into other securities, cash or other property (any of the foregoing being herein referred to as a “Transaction”), then lawful provision shall be made as part of the terms of such Transaction whereby the
holder of each share of Series B Preferred Stock then outstanding shall have the right to convert such share only into the kind and amount of securities, cash and other property receivable upon such Transaction by a holder of the number of shares of
Common Stock of the Corporation into which such share of Series B Preferred Stock could have been converted immediately prior to such Transaction. As a condition to the consummation of any Transaction, the Corporation shall require that the person
formed by such consolidation or resulting from such merger or that acquires such assets or that acquires the Corporation’s shares, as the case may be, shall make provisions in its certificate or articles of incorporation or other constituent
documents to establish such right. Such certificate or articles of incorporation or other constituent documents shall provide for adjustments which, for events subsequent to the effective date of such certificate or articles of incorporation or
other constituent documents, shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 6. The above provisions shall similarly apply to successive reclassifications, consolidations, mergers,
sales, transfers or share exchanges. 
 (g) Reservation of Shares; Transfer Taxes; Etc. Following Stockholder Approval, the
Corporation shall at all times reserve and keep available, out of its authorized and unissued stock, solely for the purpose of effecting the conversion of the Series B Preferred Stock, such number of shares of its Common Stock and other securities
free of preemptive rights as shall from time to time be sufficient to effect the conversion of all shares of Series B Preferred Stock from time to time outstanding which are then convertible. Prior to Stockholder Approval, the Corporation shall
reserve and keep available such number of shares of its Common Stock as it then has available for such reservation for conversion. The Corporation shall from time to time, in accordance with the laws of the State of Delaware, increase the authorized
number of shares of Common Stock and other securities if at any time the number of shares of Common Stock and other securities not outstanding shall not be sufficient to permit the conversion of all the then outstanding shares of Series B Preferred
Stock. The rights of the holders of the Series B Preferred Stock, and the granting of such rights by the Corporation hereunder, shall not be considered invalid solely by reason of the lack of sufficient authorized but unissued shares to 

  

 73 







 
honor the exercise of such conversion rights. If any shares of Common Stock required to be reserved for purposes of conversion of the Series B Preferred
Stock hereunder require registration with or approval of any governmental authority under any Federal or State law before such shares may be issued upon conversion or exercise, the Corporation will in good faith and as expeditiously as possible
endeavor to cause such shares to be duly registered or approved, as the case may be. The Corporation will pay any and all issue or other taxes that may be payable in respect of any issue or delivery of shares of Common Stock on conversion of the
Series B Preferred Stock. The Corporation shall not, however, be required to pay any tax that may be payable in respect of any transfer involved in the issue or delivery of Common Stock (or other securities or assets) in a name other than that in
which the shares of Series B Preferred Stock so converted were registered, and no such issue or delivery shall be made unless and until the person requesting such issue has paid to the Corporation the amount of such tax or has established, to the
satisfaction of the Corporation, that such tax has been paid. 
 The Corporation shall not take any action that would cause any equity
securities issuable upon conversion of Series B Preferred Stock immediately following such action to be other than fully paid and nonassessable. 
 (h) Prior Notice of Certain Events. In case: 
 (i) the Corporation shall authorize the granting to the holders of Common
Stock of rights or warrants to subscribe for or purchase any shares of stock of any class or of any other rights or warrants (other than any rights specified in paragraph (d)(i)(B) of this Section 6); or 
 (ii) of any reclassification of Common Stock (other than a subdivision or combination of the outstanding Common Stock, or a change in par value, or from
par value to no par value, or from no par value to par value), or of any consolidation or merger to which the Corporation is a party and for which approval of any stockholders of the Corporation shall be required, or of the sale or transfer of all
or substantially all of the assets of the Corporation or of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or other property; or 
 (iii) of the voluntary or involuntary dissolution, liquidation or winding up of the Corporation; 
 then the Corporation shall cause to be mailed to each holder of record of the outstanding Series B Preferred Stock, at such holder’s address as it shall appear upon
the stock transfer books of the Corporation, at least 15 days prior to the applicable record date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such granting of rights or warrants or,
if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such rights or warrants are to be determined, or (y) the date on which such reclassification, consolidation, merger, sale, transfer,
share exchange, dissolution, liquidation or winding up is expected to become effective, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer, share exchange, dissolution, liquidation or winding up (but neither the failure so to mail such notice nor any defect therein or in the mailing thereof, shall
affect the validity of the corporate action required to be specified in such notice). 
  

 74 







 7. Preemptive Rights. 
 (a) If the Corporation offers to sell Covered Securities (as defined below) in a public or private offering of Covered Securities solely for cash (a
“Qualified Offering”), each holder of shares of Series B Preferred Stock (a “Holder”) shall be afforded the opportunity to acquire from the Corporation, for the same price and on the same terms as such Covered
Securities are offered, in the aggregate up to the amount of Covered Securities required to enable such Holder to maintain its then-current Holder Percentage Interest (as defined below), but solely to the extent that any such issuance of shares of
Covered Securities would not result in the issuance of Covered Securities that would require a vote of the stockholders of the Corporation pursuant to the listing standards of the New York Stock Exchange or other nationally recognized stock exchange
on which shares of Common Stock are listed. As used in this Section 7, (i) “Holder Percentage Interest” means, as of any date, the percentage equal to (A) the aggregate number of shares of Common Stock
beneficially owned (with the term “beneficial ownership” having the meaning ascribed in Section 13(d)(3) and Rule 13d-3 under the Exchange Act of 1934, as amended) or otherwise held by such Holder as of such date, calculated on an
as-converted basis, divided by (B) the total number of outstanding shares of Common Stock as of such date, calculated on an as-converted basis, and (ii) “Covered Securities” means Common Stock and any securities
convertible into or exercisable or exchangeable for Common Stock, other than securities that are (A) issued by the Corporation pursuant to any employment contract, employee or benefit plan, stock purchase plan, stock ownership plan, stock
option or equity compensation plan or other similar plan where stock is being issued or offered to a trust, other entity to or for the benefit of any employees, potential employees, consultants, officers or director of the Corporation,
(B) issued by the Corporation in connection with a business combination or other merger, acquisition or disposition transaction, (C) issued with reference to the Common Stock of a subsidiary of the Corporation (i.e., a carve-out
transaction), (D) issued as a dividend or in connection with a dividend reinvestment or stockholder purchase plan, (E) issued in exchange for currently outstanding securities, or (F) issued to the United States Treasury as part of the
TARP Capital Purchase Program or any similar governmental program. 
 Prior to making any Qualified Offering of Covered Securities, the
Corporation shall give each Holder written notice of its intention (including, in the case of a registered public offering and to the extent possible, a copy of the prospectus included in the registration statement filed in respect of such),
describing, to the extent then known, the anticipated amount of securities, price (or, in the case of a registered public offering, an estimated range of prices) and other material terms upon which the Corporation proposes to offer the same. Such
Holder shall have thirty (30) days from the provision of such notice to notify the Corporation in writing that it intends to exercise such preemptive purchase rights and as to the amount of Covered Securities such Holder desires to purchase, up
to the maximum amount calculated pursuant to Section 7(a) (the “Designated Securities”). Such notice shall constitute a non-binding indication of interest of such Holder to purchase the amount of Designated Securities so
specified (or a proportionately lesser amount if the amount of Covered Securities to be offered in such Qualified Offering is subsequently reduced) at the price (or range of prices) and other terms set forth in the Corporation’s notice to it.
The failure by such Holder to respond during such thirty (30) day period shall constitute a waiver of preemptive rights in respect of such offering. The obligation of the Corporation to provide such notice shall be subject to such Holder’s
written agreement to confidentiality and restrictions on trading terms reasonably acceptable to the Corporation. 
  

 75 







 If a Holder exercises such Holder’s preemptive purchase rights provided in this
Section 7 with respect to a Qualified Offering that is an underwritten public offering or a private offering made to qualified institutional buyers (as such term is defined in Rule 144A under the Securities Act of 1933, as amended (the
“Securities Act”) for resale pursuant to Rule 144A under the Securities Act, the Corporation shall offer such Holder, if such underwritten public offering or Rule 144A offering is consummated, the Designated Securities (as adjusted
downward or, at such Holder’s option, upward to reflect the actual size of such offering when priced) at the same price as the Covered Securities are offered to the initial purchasers in such offering and shall provide written notice of such
price to such Holder as soon as practicable prior to such consummation. Contemporaneously with the execution of any underwriting agreement or purchase agreement entered into between the Corporation and the underwriters or initial purchasers of such
underwritten public offering or Rule 144A offering, such Holder shall, if it continues to wish to exercise its preemptive rights with respect to such offering, enter into an instrument in form and substance reasonably satisfactory to the Corporation
acknowledging such Holder’s binding obligation to purchase the Designated Securities to be acquired by it and containing representations, warranties and agreements of such Holder that are customary in private placement transactions and, in any
event, no less favorable to such Holder than any underwriting or purchase agreement entered into by the Corporation in connection with such offering, and the failure to enter into such an instrument at or prior to such time shall constitute a waiver
of preemptive rights in respect of such offering. Any offers and sales pursuant to this Section 7(c) in the context of a registered public offering shall also be conditioned on reasonably acceptable representations and warranties of such
Holder regarding its status as the type of offeree to whom a private sale can be made concurrently with a registered offering in compliance with applicable securities laws. 
 If a Holder exercises its preemptive rights provided in this Section 7 with respect to a Qualified Offering that is not an underwritten
public offering or Rule 144A offering (a “Private Placement”), the closing of the purchase of the Covered Securities with respect to which such right has been exercised shall be conditioned on the consummation of the Private
Placement giving rise to such preemptive purchase rights and shall take place simultaneously with the closing of the Private Placement or on such other date as the Corporation and such Holder shall agree in writing; provided that the actual
amount of Covered Securities to be sold to such Holder pursuant to its exercise of preemptive rights hereunder shall be reduced if the aggregate amount of Covered Securities sold in the Private Placement is reduced and, at the option of such Holder
(to be exercised by delivery of written notice to the Corporation within five (5) business days of receipt of notice of such increase), shall be increased if such aggregate amount of Covered Securities sold in the Private Placement is
increased. In connection with its purchase of Designated Securities, such Holder shall, if it continues to wish to exercise its preemptive rights with respect to such offering, execute an agreement containing representations, warranties and
agreements of such Holder that are substantially similar in all material respects to the agreements executed by other purchasers in such Private Placement. 
 If, prior to consummation of a Qualified Offering, the terms of the proposed issuance change with the result that the price is less than the minimum price or more than the maximum price set forth in the notice
contemplated by Section 7(b) or the other principal terms are more favorable in any material respect to the prospective purchaser than those set forth in such notice, it shall be necessary for a separate notice to be furnished, and the
terms and provisions of this Section 7 separately complied with. 
  

 76 







 Anything to the contrary in this Section 7 notwithstanding, the preemptive right to purchase
Covered Securities granted by this Section 7 as to a Holder shall terminate as of and not be available for any offering that commences at any time after the date on which such Holder offers, sells, pledges, or otherwise transfers any of
the shares of Series B Preferred Stock then held by such Holder, including by way of entry into any swap or other agreement or transaction that hedges or transfers, in whole or in part, directly or indirectly, the economic consequence of ownership
of such shares. In addition, the preemptive rights granted hereunder shall only apply to the initial Holder of the Covered Securities. 
 C. Headings. 
 The headings of the Sections of this Certificate are for convenience of reference only and shall not
define, limit or affect any of the provisions hereof. 
 [SIGNATURE PAGE FOLLOWS] 
  

 77 







 IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed in its name and on
its behalf on this ____ day of ____________, 2009. 
  

			
	THE COLONIAL BANCGROUP, INC.
		
	By:	 	 
		 	Name:
		 	Title:


  

 78